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ABSTRACT
Background
In clinical practice, Systematic COronary Risk Evaluation (SCORE) risk prediction functions 
and charts are used to identify persons at high risk for cardiovascular diseases (CVD), 
who are considered eligible for drug treatment of elevated blood pressure and serum 
cholesterol levels. These functions use classical risk factors (age, sex, smoking, blood 
pressure and the ratio of total-to-HDL-cholesterol) to predict absolute 10-year risk of CVD 
mortality rather than total (fatal plus nonfatal) CVD. The aim of this thesis was to improve 
cardiovascular risk prediction in the Netherlands, and to correctly classify high-risk persons.
Methods
We primarily used data from the Monitoring Project on Chronic Disease Risk Factors 
(MORGEN project) of the National Institute for Public Health and the Environment (RIVM). 
Risk factor data of more than 20,000 men and women aged 20-65 years were collected 
between 1993 and 1997. Ten-year follow up data on CVD mortality and morbidity were 
obtained from Statistics Netherlands and the National Hospital Discharge Register, 
respectively. Risk functions were developed using multivariable Cox proportional hazard 
models.
Results
The SCORE risk function for low-risk countries was the best predictor of CVD mortality 
in the Netherlands. Total CVD was approximately four times higher than CVD mortality. 
Obesity (BMI ≥ 30 kg/m2) and parental history of myocardial infarction before age 70 were 
independent predictors of total CVD. Risk functions predicting risk of CVD mortality and 
total CVD, and their ability to discriminate between future cases and non-cases, did not 
differ. Of the high-risk persons with a CVD mortality risk of at least 5%, approximately 20% 
developed a nonfatal or fatal CVD event during 10 years of follow-up. When a cut-off point 
of 2% CVD mortality was used, approximately 10% of the high-risk persons developed a 
CVD event. When obesity and parental history of MI were added to the classical risk factor 
function, correct risk classification improved by 5%. This improvement in risk prediction 
was mainly due to obesity. 
Conclusions
Discrimination between future cases and non-cases did not improve by expanding the 
endpoint of risk prediction from fatal CVD to total CVD. Adding obesity and parental 
history to the classical risk factor functions slightly increased the number of correctly 
classified persons.
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Introduction
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The Health Council of The Netherlands led the way on cardiovascular risk management 
30 years ago by issuing advice on treatment of hypertension,1,2 followed by an advice on 
cholesterol.3 Almost at the same time, guidelines for hypertension and cholesterol were 
developed by the former Institute of Health Care Improvement (CBO) in cooperation 
with the Netherlands Heart Foundation (NHF).4,5 The Netherlands College of General 
Practitioners (NHG) developed guidelines specifically for general practitioners.6,7 In 
2006, the first guideline on integrated cardiovascular risk management was released, a 
collaborative activity involving CBO, NHG and NHF.8-10 Revision of guidelines took place 
after 2-8 years, depending on new developments e.g. publication of landmark studies on 
new generations of drugs, or inspired by publications or updates of WHO, American or 
European guidelines. In the past 30 years, eight guidelines on hypertension,1,2,4,6,11-14 seven 
on cholesterol,3,5,15-18 and two on cardiovascular risk management have been published in 
the Netherlands (Figure 1.1).8-10,19 
An historic overview is presented of Dutch guideline development on hypertension and 
cholesterol, lately integrated into cardiovascular risk management. Emphasis is on consensus 
guidelines for primary prevention, in high-risk persons without manifest cardiovascular 
diseases (CVD). The focus is on changes in blood pressure levels for drug treatment of 
hypertension, on cholesterol levels for drug treatment of hypercholesterolemia and on 
the introduction of risk charts to identify persons at high risk of CVD.
Guidelines on hypertension 1978–2003 
The first advice on treatment of hypertension was published by the Health Council (1978, 
1983).1,2 Hypertension was defined as a diastolic blood pressure of 115 mmHg or higher. 
Persons with hypertension were advised to change their lifestyle and were eligible for drug 
treatment. Persons with blood pressure values between 100–115 mmHg were eligible for 
drug treatment, when lifestyle measures did not effectively lower blood pressure. First 
choice of drugs were diuretics (thiazides) and beta-blockers. These recommendations 
were based on the results of the Hypertension Detection and Follow-up Program from 
the USA20 and the Australian therapeutic trial in mild hypertension.21
New insights into the risk of moderately elevated blood pressure levels,22 were the 
justification for the lower thresholds of drug treatment in the 1990 CBO/NHF-consensus4 
and the 1991 NHG-guideline.6 Now persons with diastolic blood pressure levels exceeding 
105 mmHg were eligible for drug treatment. Persons with levels between 95–104 mmHg 
were treated only when additional risk factors were present, e.g. smoking, diabetes, 
hypercholesterolemia, high body mass index (BMI) or a positive family history of CVD. 
The presence of one additional risk factor was recommended in the CBO-guideline, and 
two in the NHG-guideline. For pharmacological treatment, four classes of drugs were 
available: diuretics, beta-blockers, (ACE)-inhibitors and calcium-antagonists. At that time, 
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there was only definitive evidence that the first two classes of antihypertensives reduced 
CVD incidence in patients with hypertension. 
In the 1990s, several meta-analyses of trials in persons with hypertension were 
published.23,24 Evidence was accumulating, that treatment of systolic hypertension reduced 
CVD incidence, also in the elderly. The 1997 and 1999 NHG-guidelines (first and second 
revisions)11,12 proposed also that persons with systolic blood pressure levels of 180 mmHg 
or higher were eligible for drug treatment. 
The scientific evidence for elevated systolic blood pressure as a CVD risk factor, the 
release of the WHO-criteria for management of hypertension25 and growing interest in 
integrated risk factor management, were reasons for the revision of the CBO-guideline 
on high blood pressure, which was released in 2000.13 In the meantime, the focus on 
treatment of diastolic shifted to systolic blood pressure and on total cholesterol to the 
ratio of total to HDL cholesterol. The Framingham risk tables were introduced as a first 
step towards multifactorial risk management (Figure 1.2).26 Risk assessment was based 
on age, sex, smoking status, systolic blood pressure, total to HDL-cholesterol ratio and 
diabetes. Classification of those at high risk was based on a combination of elevated 
levels of systolic blood pressure with a high absolute risk of CVD, and on elevated serum 
cholesterol levels with a high absolute risk of CHD. A positive family history of CVD below 
age 60 was an additional risk factor and a reason to start drug treatment at a lower level of 
risk. The following stepwise approach for treatment of patients with absolute risk of CVD 
≥ 20% or hypertension (≥ 180 mmHg) was recommended: 1. diuretics (thiazides), 2. beta-
blocker, 3. RAS-inhibitors. The first choice for diuretics was based on the Antihypertensive 
and Lipid-Lowering Treatment to Prevent Heart Attack trial.27 In elderly people, diuretics 
are most effective, with less adverse effects. The 2003 NHG-guideline (third revision)14 
was based on the 2000 CBO/NHF-guideline.13
Guidelines on high cholesterol 1987-1999
The first guidelines on serum total cholesterol were characterised by a unifactorial 
approach. Important evidence on the relationship between serum cholesterol and coronary 
heart disease (CHD) mortality came from the 350,000 screenees of the Multiple Risk Factor 
Intervention Trial.28 This study showed that this relationship was strong and graded. Soon 
thereafter, the results of the Lipid Research Clinic-trial were published on the effect of 
the first generation of cholesterol lowering drugs, the bile acid sequestrant resins.29 This 
trial showed a mean decrease of 8% in serum total cholesterol and 12% in LDL-cholesterol 
resulting in a 19% CHD incidence reduction. These results formed the basis of the first 
consensus report on cholesterol in the Netherlands, published in 1987.5 Total cholesterol 
levels of at least 6.5 mmol/l were considered elevated and levels of 8 mmol/l and higher 
strongly elevated. The cornerstone of treatment of high cholesterol levels was a healthy 
12
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diet. Cholesterol-lowering medication could be considered, but prescription was restricted 
mainly to those with strongly elevated cholesterol levels. 
Anticipating the introduction of statins, a new generation of cholesterol synthesis inhibitors, 
the Health Council performed a cost-effectiveness analysis in 1990.3 Costs per life year gained 
were higher for cholestyramin than for simvastatin, and costs for both drugs were much 
higher than that of a cholesterol-lowering diet. The Health Council advice and the NHG 1991 
guideline7 used the same cut-off points for elevated serum cholesterol levels as recommended 
by the 1991 first revision of the CBO cholesterol consensus (≥ 8 mmol/l).15 Additionally, their 
advice on prescription of cholesterol-lowering medication depended for the first time not only 
on these elevated serum cholesterol levels, but also on the presence of at least one additional 
risk factor. Statins (simvastatin and pravastatin) became the first choice of drugs for patients 
with cholesterol levels above 8 mmol/l. For those with lower cholesterol levels the bile acid 
sequestrant resins remained first choice. At that time, it was demonstrated that statins 
lowered LDL-cholesterol levels by 25–35%, and could induce regression of atherosclerosis.30 
However, evidence on the effect on CHD incidence had still to be obtained. 
In the mid 1990s results of important milestone studies on cholesterol treatment were 
published: 4S, CARE, WOSCOPS, LIPID and AFCAPS trials.31-33 These trials showed that statins 
reduced CHD incidence by 25–35%. This led to revision of the CBO cholesterol consensus in 
1998.16 The Framingham risk tables predicting 10-year CHD risk, were used to identify high 
risk persons (Figure 1.2). These tables were derived from the ones used by the European 
Societies of Cardiology, Atherosclerosis and Hypertension.34,35 Risk prediction was based 
on age, sex, smoking status, total-to-HDL cholesterol ratio, diabetes and hypertension. 
Indication for drug treatment of hypercholesterolemia was no longer based on serum 
cholesterol levels alone, but also on age-specific risk scores. Age-specific cut-off points for 
drug treatment were formulated, based on cost-effectiveness analyses. The cut-off point 
of 10-year CHD incidence increased from > 25% at age 40 to 35–40% at age 70. In case of a 
positive family history of CHD at age < 60, medication could already be prescribed at a 5% 
lower cut-off point of CHD risk. The first choice of drugs were statins. The first revision of 
the NHG guideline, published in 199917 was based on the 1998 CBO-consensus.16
In 2000, the Health Council advised the Minister of Health on indications for cholesterol 
treatment with statins.18 The Council recommended to use a ‘risk score of 8’ as cut-off 
point for treatment with statins. This means that persons with a total-to-HDL cholesterol 
ratio higher than 8, or those with a ratio higher than 7 plus one additional risk factor, or 
a ratio of 6 with two additional risk factors (e.g. smoking and hypertension) qualified for 
statin treatment. The major reason not to recommend risk tables was that the Council 
preferred a simplified method to select high risk persons, without the need to consult 
tables. Only a minority of the committee was in favour of considering costs for determining 
indications for cholesterol-lowering therapy.
13
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Guidelines on cardiovascular risk management 2006-2011 
In the first decade of the 21st century, the shift from unifactorial to multifactorial risk 
factor management was completed. In 2003, the results of the first large trial on the 
effects of a powerful new statin, atorvastatin were published.36 This statin was tested in 
persons with hypertension, average or below average serum cholesterol levels, and at 
least three additional risk factors. Atorvastatin treatment reduced major cardiovascular 
events by 35%, major cerebrovascular events by 48% and all-cause mortality by 15%. In 2006, 
the CBO and NHG released the first ‘Multidisciplinary Guideline on CardioVascular Risk 
Management in clinical practice’.9 In line with the European guideline on Cardiovascular 
Disease Prevention in Clinical Practice,37,38 the earlier used US Framingham risk tables were 
replaced by those of the European based Systematic COronary Risk Evaluation (SCORE)-
system (Box 1.1).37 The SCORE-group adapted the risk function for the Netherlands (Figure 
1.2). The risk factors in the SCORE tables were the same as those in the Framingham risk 
tables, except for diabetes. 
The introduction of the SCORE-risk charts meant a change from predicting 10-year risk 
of CHD incidence to 10-year risk of CVD mortality. The cut-off point for identifying those 
who needed drug treatment for elevated blood pressure and cholesterol was a 10-year 
CVD mortality risk of ≥ 10%.9 This was higher than the cut-off point used in the European 
guidelines (≥ 5%).38,39 This higher cut-off point was based on cost-effectiveness analyses 
and on preventing an increase in the work load of general practitioners. At a risk between 
5% and 10%, drug treatment could be started when additional risk factors – such as clinical 
signs of organ damage, a positive family history of CVD < 60 years, a BMI > 30 kg/m2 or 
a waist circumference > 88 cm for women and > 102 cm for men – were present. Based 
14
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Box 1.1 SCORE risk charts
Risk charts of the SCORE (Systematic COronary Risk Evaluation) project were derived 
from a large database of prospective studies including over 200,000 persons in Europe. 
Risk equations for high-risk countries were based on data collected in cohorts from 
Denmark, Finland and Norway and for low-risk countries from Belgium, Italy and Spain.37 
Almost all participants in these cohorts were recruited in the 1970s and early 1980s. 
At the time of construction of these SCORE charts, the Netherlands was considered a 
high-risk country. The SCORE-group adapted the risk function for the Netherlands, using 
the national percentage of smokers and average systolic blood pressure and serum 
total and HDL-cholesterol levels derived from a Dutch survey carried out between 1998 
and 2001 (Regenboog-project; RIVM) and using national CVD mortality statistics from 
2000 (WHO mortality database).
15
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Figure 1.2 Impression of risk charts in the 1998 Guideline on Cholesterol, the 2000 Guideline on 
High blood pressure and the 2006 Guideline on Cardiovascular Risk Management.
on cost-effectiveness, drug treatment of elevated blood pressure was started with a low 
dose of a diuretic and, if the targets were not reached, other classes of antihypertensive 
drugs could be added. Treatment of elevated serum cholesterol started with simvastatin 
or pravastatin. When the targets were not reached, atorvastatin was not recommended 
for those without CVD or type II diabetes, because of the limited evidence for an effect 
on CVD endpoints and on safety.
After the 2006 guideline on CVRM, results on the effectiveness of drug treatment of blood 
pressure and serum cholesterol cumulated exponentially, and several meta-analyses 
were published. The effectiveness of blood pressure-lowering drugs in the prevention 
of CVD was demonstrated in 27 randomised clinical trials in more than 100,000 persons 
with no history of CHD, all classes of antihypertensive drugs showed similar effects in 
reducing CVD events.40 The benefit of statin therapy in about 70,000 persons without CVD 
was investigated in a meta-analysis including trials with the first generations of statins: 
simvastatin (HPS), lovastatin (AFCAPS/TexCAPS) and pravastatin (WOSCOPS, PROSPER, 
ALLHATT-LTT, MEGA), and with the more recently developed statins, atorvastatin (ASCOT-
LLA, CARDS, ASPEN) and rosuvastatin (JUPITER).41 Major coronary events were reduced 
by 30%, major cerebrovascular events by 19%, and all-cause mortality by 12%. However, 
CHD mortality was not significantly reduced.
The first revision of the multidisciplinary guideline on cardiovascular risk management 
will be published in 2011.19 A shift was made from risk tables with CVD mortality to total 
CVD incidence. Nonfatal endpoints included were myocardial infarction, stroke and heart 
failure. This also meant a shift in cut-off points for high risk to ≥ 20%, for intermediate risk 
to 10–20%, and for low risk to < 10%. For those at intermediate risk, one strongly and two 
or more moderately elevated CVD risk factors can be an indication for drug treatment. 
Among the strongly elevated risk factors were having at least two family members with 
a history of CVD below age 65 or at least one with a history of CVD below age 60, BMI > 
35 kg/m2 and a sedentary lifestyle. The mildly elevated risk factors included having one 
family member with a history of CVD below age 65, BMI 30–35 kg/m2 and less than 30 
minutes physical activity on five or less days a week. Also diminished kidney function is 
considered an additional risk factor. For treatment of elevated blood pressure levels, 
all classes of drugs can be used, with a mild preference for diuretics in those without 
CVD. A stepwise approach was recommended. Based on cost-effectiveness, drug 
treatment of elevated serum cholesterol levels started with simvastatin. If the treatment 
goal of LDL ≤ 2.5 mmol/l is not reached, a switch to rosuvastatin, or atorvastatin is 
recommended.
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Conclusion
Cardiovascular risk management has changed over the past 30 years from unifactorial 
treatment of severe hypertension (diastolic blood pressure ≥ 115 mmHg) and severe 
hypercholesterolemia (≥ 8 mmol/l), to multifactorial risk factor treatment based on overall 
cardiovascular risk and treatment of elevated systolic blood pressure and/or serum total 
and HDL-cholesterol levels. Nowadays, the concept that “the lower the risk factors, the 
lower the absolute risk” is the leading paradigm in CVD prevention. 
AIM AND RESEARCH QUESTIONS
The overall aim of this thesis is to improve cardiovascular risk prediction in the Netherlands 
and to correctly identify persons at high risk for CVD, who are eligible for drug treatment 
of elevated blood pressure and/or serum cholesterol levels. This thesis deals with the 
following questions raised during the development of the first multidisciplinary guideline 
on Cardiovascular Risk Management in clinical practice (CVRM),8 published in 2006:
1. Which SCORE risk function fits best for the Netherlands?
2. What are the consequences of a change from predicting CVD mortality to total CVD 
(fatal plus nonfatal) for identifying high-risk persons?
3. What is the added value for risk prediction of including additional risk factors (obesity 
and parental history of myocardial infarction) in the classical risk function with total 
CVD as endpoint?
To answer these questions data were used from two monitoring studies of the National 
Institute for Public Health and the Environment (RIVM): the Monitoring Project on 
Cardiovascular Disease Risk Factors, of which the risk factor data were collected in 
1987–1992 and the Monitoring Project on Chronic Disease Risk Factors of which the risk 
factors were collected in 1993–1997.42,43 The latter project is the RIVM contribution to the 
EPIC study.44 Mortality and morbidity data were collected until 2006. Also data from the 
EPIC-NL cohort were analysed, a combined database of the EPIC cohort of the RIVM and 
the PROSPECT cohort of the University Medical Centre of Utrecht.44 
To deal with the first question, we examined how well 10-year CVD mortality observed 
in Dutch cohorts is predicted by three different risk functions: the SCORE risk functions 
for low-risk European regions, the SCORE risk function for high-risk European regions 
(including the Netherlands) and the nationally adapted Dutch SCORE risk function, 
prepared by the SCORE group for the 2006 guideline on CVRM (Chapter 2).
To improve cardiovascular risk prediction and correctly classify high-risk persons for 
CVD, we investigated the impact of expanding the endpoint of risk prediction from CVD 
17
Introduction
Chapter 1
mortality to CVD incidence and of adding additional risk factors to the risk function. Two 
promising risk factors are obesity and a parental history of myocardial infarction (MI). First, 
we conducted studies to examine the associations between measures of overweight and 
risk of CVD (Chapter 3) and between parental history of MI and CVD risk (Chapter 4). We 
used different definitions of these risk factors to obtain the best predictor.
Subsequently, the impact of expanding the endpoint from CVD mortality to total CVD in 
classical cardiovascular risk factor models is described (Chapter 5). The added value for 
risk prediction was examined of including obesity and parental history of MI into classical 
risk factor functions (Chapter 6). In the final chapter the contribution of our research to 
cardiovascular risk management in the Netherlands is described and promising future 
developments in cardiovascular risk prediction are discussed (Chapter 7).
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ABSTRACT
Background: In Europe, for primary prevention of cardiovascular diseases (CVD), the 
Systematic COronary Risk Evaluation (SCORE) risk charts for high-risk and low-risk 
regions (SCORE-high and SCORE-low, respectively) are used. For the Dutch ‘Clinical 
Practice Guideline for Cardiovascular Risk Management’ an adapted SCORE risk chart 
(SCORE-NL) was developed in collaboration with the SCORE group. We evaluated these 
three SCORE equations using risk factor and mortality data of a Dutch prospective 
cohort study with 10 year follow-up. 
Methods: Baseline data were collected between 1987 and 1997 in 32,885 persons aged 
37.5–62.5 years. Vital status was checked and causes of death were obtained from 
Statistics Netherlands. On the basis of the level of risk factors, the expected number 
of CVD deaths was calculated by applying the three SCORE equations and compared 
with the observed number.
Results: The observed CVD mortality was three-fold higher in men (n = 242; 1.6%) than 
in women (n = 83; 0.5%). On the basis of SCORE-NL, 8.5% of the men and 0.8% of the 
women had a CVD mortality risk of 5% or more. The ratio of the observed-to-expected 
number of CVD deaths was 0.75 for men and 0.55 for women using SCORE-NL, 0.54 
and 0.56 using SCORE-high and 1.11 and 0.95 using SCORE-low.
Conclusion: At the population level, SCORE-low predicts the number of CVD deaths 
well, whereas both SCORE-NL and SCORE-high overestimate the number of CVD deaths 
by a factor 1.5–2.
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INTRODUCTION
Current guidelines for primary prevention of cardiovascular disease (CVD), recommend 
treatment of hypercholesterolemia and hypertension based on the estimated 10-year 
absolute risk for fatal CVD, taking into account an individual’s overall risk profile, assessed 
on sex, age, smoking, systolic blood pressure and serum total cholesterol or total /HDL-
cholesterol ratio.1-3
In the European Union (EU)-funded Systematic COronary Risk Evaluation (SCORE) project, 
a CVD risk function was developed based on European risk factor and CVD mortality data.4 
Risk charts were presented to estimate 10-year absolute risk of fatal CVD in populations at 
low and high-CVD risk. The Netherlands was regarded as a high-risk region. On request, the 
SCORE-group adapts its risk functions to recent national risk factor levels and CVD mortality 
statistics of European countries. Such a nationally adapted risk chart for The Netherlands 
was presented in the Dutch Clinical Practice Guideline for Cardiovascular Risk Management.3
On the basis of data from two large longitudinal population-based studies carried out in 
the late 1980s and 1990s, we evaluated the performance of the SCORE risk equations for 
the Dutch situation. We compared the observed CVD mortality with the expected CVD 
mortality based on the SCORE risk equations, both the equation for high-risk regions 
(SCORE-high) and that for low-risk regions (SCORE-low), and the risk function adapted to 
more recent national risk factor data and CVD mortality statistics (SCORE-NL). Implications 
for use and adaptation of risk charts in European countries are discussed.
METHODS
Study populations and data collection 
Two monitoring projects on CVD risk factors, using the same methods, were carried out 
in The Netherlands between 1987 and 1997. Baseline cardiovascular risk factor data were 
collected in about 42,000 men and women aged 20–59 years during 1987–1992 in the 
Monitoring Project on Cardiovascular Disease Risk Factors and in approximately 21,000 
men and women aged 20–65 years during 1993-1997 in the Monitoring Project on Chronic 
Disease Risk Factors (MORGEN-Project).5,6 
The surveys were approved by the Medical Ethics Committees of the Academic Hospital 
Leiden and TNO Prevention and Health, Leiden, respectively. Participants signed an 
informed consent form for collecting additional medical information. The projects were 
carried out in random population samples of Amsterdam and Maastricht (response rates 
33% and 43%, respectively). In Doetinchem, during 1993–1997 participants of the first survey 
in 1987–1992, were reinvited. In this analysis for Doetinchem only risk factor data collected 
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in 1993–1997 were used (response rate 68%). To enable comparison with SCORE, this 
analysis included data of 32,887 persons aged 37.5–62.5 years at baseline and excluded 
577 persons with a self-reported history of myocardial infarction. 
Information on demographic variables, disease history, use of medication, and lifestyle 
factors was obtained by standardized questionnaires. Serum total and HDL-cholesterol 
were measured at a laboratory that is a permanent member of the international Cholesterol 
Reference Method Laboratory Network (Erasmus Medical Centre, Rotterdam).7,8 Blood 
pressure was measured twice by a trained technician at the right upper arm with the 
participant in sitting position using a random zero sphygmomanometer. Systolic blood 
pressure was recorded at the first and diastolic blood pressure at the fifth Korotkoff phase. 
The second measurement was taken after counting the resting heart rate for 30s. The 
mean of both measurements was used in the analyses. Information on smoking status 
was obtained from a questionnaire and dichotomized into ‘current’ and ‘non-smoker’. 
Vital status was checked through record linkage with the national population register. 
Only 66 persons were lost to follow up, 694 persons emigrated and were censored at the 
date of emigration. Data on CVD mortality during follow-up were obtained from Statistics 
Netherlands. Cases were censored at the date of death. Other participants were censored 
at the end of follow-up (at a maximum of 11 years), with an average of 10 years. Until 
January 1, 1996 we used the same International Classification of Diseases (ICD) 9 codes 
as applied in the SCORE project and thereafter corresponding ICD 10 codes.
SCORE project
The aim of the SCORE project was to construct risk equations for estimating an individual’s 
10-year risk of fatal CVD, based on a combination of risk factors4 to assist clinicians in 
cardiovascular risk management for primary prevention. SCORE equations for high-risk 
regions were based on baseline survival data collected in cohorts from Denmark, Finland 
and Norway (SCORE-high) and for low-risk regions from Belgium, Italy and Spain (SCORE-
low). Almost all participants in these cohorts were recruited in the 1970s and early 1980s. 
At the time of construction of these SCORE charts, The Netherlands was considered a 
high-risk region. For the Dutch Clinical Guideline on Cardiovascular Risk Management, the 
SCORE group adapted the SCORE equation as described by Conroy et al.4 in 2006 by using 
the national percentage of smokers and average systolic blood pressure and serum total 
and HDL-cholesterol levels derived from a Dutch survey carried out by municipal health 
services in approximately 4,000 participants between 1998 and 2001 (REGENBOOG-
project).9 For this purpose, national CVD mortality statistics of 2000 were obtained from 
the WHO mortality database. The nationally adapted SCORE risk function (SCORE-NL) 
calculates risk based on age, sex, smoking, systolic blood pressure, and the natural log 
of the ratio of total/HDL-cholesterol.3 
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In the SCORE project, CVD mortality was defined as a combination of coronary heart disease 
(CHD) (ICD 9: 401–414, 798.1 and 798.2) and noncoronary CVD (ICD 9: 426–443, with the 
exception of 426.7, 429.0, 430.0, 432.1, 437.3, 437.4 and 437.5). Noncoronary CVD includes 
ischemic cerebrovascular accident, congestive heart failure and peripheral arterial disease.
Statistical analysis 
The cumulative 10-year incidence of fatal CVD (observed CVD mortality) was calculated. 
For all respondents, their individual 10-year risk for fatal CVD was calculated as follows, 
using the nationally adapted risk function SCORE-NL: 
Expected CVD risk = (1-Survivalbaseline*e
[β1*(smoking status) + β2*(systolic blood pressure –  140) + 
β3 *(ln ratio total/HDL-cholesterol – ln 5] )*100. 
Age-dependent and sex-dependent baseline survival coefficients, and the β-coefficients 
were provided by the SCORE group. Subsequently, the expected total number of CVD 
deaths based on this nationally adapted SCORE risk equation (expNL) was calculated.
To estimate the risk according to SCORE-high and SCORE-low, the expected 10-year 
risk estimates for fatal CVD were based on baseline survival coefficients for CHD and 
noncoronary CVD from SCORE low-risk and high-risk regions separately, and on coefficients 
for men and women from a pool of 12 European cohorts participating in the SCORE project 
(Appendix A, Table A; Conroy et al., 2003).4 The total effect of smoking, serum total 
cholesterol, and systolic blood pressure was calculated by applying the β-coefficients of 
the SCORE equation as mentioned in Table B.4 More detailed coefficients were provided 
by the SCORE group. The expected 10-year risk for fatal CVD was obtained by applying 
the SCORE equations for high-risk and low-risk regions (expH, expL) on the individually 
measured systolic blood pressure value, the serum total cholesterol levels, and the smoking 
status of all respondents of the Dutch cohort. 
The observed number of fatal CVD in the Dutch cohort (observed) and the expected 
number of fatal CVD based on the nationally adapted SCORE risk equation (expNL) 
and the SCORE equations for high-risk and low-risk regions (expH, expL), were plotted 
by categories of absolute risk according to the nationally adapted SCORE-NL function. 
Subsequently, the ratio observed/expected number of fatal CVD was calculated for the 
different risk functions.
To evaluate the impact of applying the different risk functions and thresholds for 
treatment on the number of persons eligible for pharmacological treatment, we present 
the percentage of respondents with a risk of  5–10 % and 10% or higher. These thresholds 
are frequently applied in European guidelines for cardiovascular risk management1,2 and 
in the Netherlands.3 In addition, risk charts for men and women aged 55 years, based on 
three different risk functions are presented.
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For all analyses SAS 9.1 by SAS Institute Inc. (Cary, North Carolina, USA) 2002–2003 was 
used.
RESULTS
Description of the study population
Of the total study population of 32,885 persons, 60% was examined between 1987 and 1992 
and 40% between 1993 and 1997; 47% was men and 53% women (Table 2.1). The differences 
in risk factors levels between men and women were small with the exception of a 5 mmHg 
higher mean systolic blood pressure and a 0.3 mmol/l lower mean HDL-cholesterol in men. 
Almost 40% of the men and women smoked. 
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Table 2.1 Baseline CVD risk factors [1987–1997, mean (SD) or percentage] and absolute 10-year 
CVD mortality risk in 32,887 men and women aged 37.5–62.5 years without a history of myocardial 
infarction in two Dutch population-based cohorts
BMI, body mass index; CHD, coronary heart disease; CVD, cardiovascular disease; SCORE-NL, Systematic 
COronary Risk Evaluation nationally adapted; SBP, systolic blood pressure. 
*Noncoronary CVD includes stroke, peripheral arterial disease and heart failure.
Men
(n = 15,385)
Women
(n = 17,500)
Age (years) 49 (6.5) 49 (6.6)
Body mass index (kg/m2)
Overweight (BMI ≥ 25 kg/m2) (%)
26.0 (3.4)
59.1
25.6 (4.3)
48.0
Serum total cholesterol (mmol/l) 5.7 (1.1) 5.7 (1.1)
Hypercholesterolemia (≥ 6.5 mmol/l) (%) 
Cholesterol lowering medication (%)
22.3
1.0
22.0
0.8
HDL-cholesterol (mmol/l) 1.1 1.4
Systolic blood pressure (mmHg) 126 (15.9) 121 (17.0)
Hypertension (SBP ≥ 160 mmHg) (%)
Blood pressure lowering medication (%) 
8.0
6.0
6.3
7.3
Current smokers (%) 38 37
Self-reported diabetes mellitus (%) 1.6 1.4
CVD deaths, n (%)
CHD deaths, n (%)
Noncoronary CVD deaths*, n 
242 (1.57)    
166     
76     
83 (0.48)
52
31
SCORE-NL risk 5–10 (%)
SCORE-NL risk > 10% (%)
7.4
1.2
0.7
0.05
SCORE-high risk 5–10 (%)
SCORE-high risk > 10% (%)
13.1
3.3
0.8
0.09
SCORE-low risk 5–10 (%)
SCORE-low risk > 10% (%)
2.9
0.2
0.1
0.02
Observed 10-year incidence of fatal CVD 
During 10 years of follow-up, 1,459 persons died, of whom 325 died from CVD (Table 2.1). 
CVD mortality was three-fold higher in men than in women. Ten-year CVD mortality was 
almost twice as high in persons recruited in the period 1987–1992 compared with those 
recruited in the period 1993–1997 both in men (1.9% versus 1.1%) and in women (0.6% versus 
0.3%), whereas age distributions were similar in both study populations.
Observed and expected CVD mortality risk 
The observed number of CVD deaths in this Dutch cohort was only half the number of CVD 
deaths expected by SCORE-NL in women (Obs/ExpNL = 0.55) and three-quarters in men 
(Obs/ExpNL = 0.74). The observed number of CVD deaths was half that predicted by SCORE-
high (Obs/ExpH = 0.54 for men and 0.56 for women) (Figure 2.1). This overestimation by 
SCORE-NL and SCORE-high was present in almost all risk categories and in both men and 
women. The observed CVD mortality risk compared well with the expected risk based on 
SCORE-low (Obs/ExpL = 1.1 for men and 0.95 for women) (Figure 2.1). 
Implications for risk factor treatment
On the basis of different SCORE equations, the percentage of persons with a risk above 5% 
varied in men between 3% for SCORE-low and 16% for SCORE-high (Table 2.1). For women 
these percentages were 0.1% and 0.8%. When a risk of 10% as cut-off point for treatment 
was taken, the percentage of men eligible for treatment varied between 0.2% for SCORE-
low and 3.2% for SCORE-high. In women these percentages were 0.02% and 0.09%. The 
number of persons with risk above 5% and 10%, respectively, based on SCORE-NL was in 
between that of SCORE-low and SCORE-high. Using SCORE-high, 16 times more men and 
4.5 times more women had a risk of 10% or higher, as compared with using SCORE-low. A 
similar pattern was found for men with a risk of 5% or higher, whereas for SCORE-NL and 
SCORE-high in women no difference was observed.
Figure 2.2 shows the 10-year absolute CVD mortality risk charts for men and women aged 
55 years by smoking, the ratio of serum total /HDL-cholesterol (SCORE-NL) or serum total 
cholesterol (SCORE-high and SCORE-low), and systolic blood pressure based on SCORE-NL, 
SCORE-high and SCORE-low. According to the Dutch Clinical Guideline, based on SCORE-
NL, a male smoker aged 55 years with a systolic blood pressure of 160 mmHg, has a risk 
of more than 10% when the ratio total /HDL cholesterol is 8 or higher and should therefore 
be pharmacologically treated. On the basis of SCORE-high he should be treated when 
serum total cholesterol is 6 mmol/l or higher. By applying SCORE-low a men with these 
characteristics would not be eligible for pharmacological treatment.
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Figure 2.1 Observed and expected absolute 10-year cardiovascular disease (CVD) mortality risk (%) 
in 15,385 men and 17,502 women from two Dutch population based cohorts, examined in 1987–
1997, by risk categories based on the nationally adjusted risk equation (SCORE-NL).
E, expected; O, observed; SC-H, SCORE-high; SC-L, SCORE-low; SC-NL, SCORE-nationally adjusted.
# at risk    5,666 4,086 2,341 1,979 1,135 178
O/E SC-H 0.26 0.43 0.65 0.59 0.64 0.51
O/E SC-L  0.55 0.89 1.33 1.20 1.29 1.01
O/E SC-NL   0.35 0.61 0.92 0.82 0.85 0.66
# at risk  12,619  3,217 1,001 531 123
O/E SC-H 0.62 0.45   0.46     0.80 0.51
O/E SC-L 1.07 0.77   0.80       1.34 0.85
O/E SC-NL 0.54 0.49   0.50      0.81 0.52
Women
Men
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Figure 2.2 Ten-year risk chart of fatal cardiovascular disease (CVD) in male and female smokers 
and nonsmokers aged 52.5–57.5 years by serum total cholesterol or ratio total/HDL-cholesterol 
and systolic blood pressure category based on the nationally adjusted risk equation (SCORE-NL), 
SCORE-high, and SCORE-low risk regions. 
SBP, systolic blood pressure in mmHg; chol, serum total cholesterol in mmol/l (SCORE-low, SCORE-
high); ratio, serum total cholesterol (mmol/l)/HDL-cholesterol (mmol/l) (SCORE-NL).
Men
Women
Nonsmoker, aged 55 years Smoker, aged 55 years
SCORE-NL SBP
4 5 6 7 8 180 8 10 11 13 15
3 4 4 5 6 160 6 7 8 9 11
2 3 3 4 4 140 4 5 6 7 8
2 2 2 3 3 120 3 4 4 5 5
4 5 6 7 8 Ratio 4 5 6 7 8
SCORE-high
6 7 8 10 12 180 12 13 16 19 22
4 5 6 7 8 160 8 9 11 13 16
3 3 4 5 6 140 5 6 8 9 11
2 2 3 3 4 120 4 4 5 6 8
4 5 6 7 8 Chol 4 5 6 7 8
SCORE-low
3 4 4 5 6 180 6 7 8 10 12
2 2 3 3 4 160 4 5 6 7 8
1 2 2 2 3 140 3 3 4 5 6
1 1 1 2 2 120 2 2 3 3 4
4 5 6 7 8 Chol 4 5 6 7 8
Nonsmoker, aged 55 years Smoker, aged 55 years
SCORE-NL SBP
2 3 3 4 4 180 4 5 6 7 8
2 2 2 3 3 160 3 4 4 5 5
1 1 2 2 2 140 2 3 3 3 4
1 1 1 1 1 120 1 2 2 2 3
4 5 6 7 8 Ratio 4 5 6 7 8
SCORE-high
2 2 3 3 4 180 4 5 5 6 7
1 2 2 2 3 160 3 3 4 4 5
1 1 1 1 2 140 2 2 2 3 3
1 1 1 1 1 120 1 1 2 2 2
4 5 6 7 8 Chol 4 5 6 7 8
SCORE-low
1 1 2 2 2 180 3 3 3 4 4
1 1 1 1 1 160 2 2 2 3 3
1 1 1 1 1 140 1 1 1 2 2
0 0 1 1 1 120 1 1 1 1 1
4 5 6 7 8 Chol 4 5 6 7 8
risk ≥ 10% risk 5–10% risk < 5%
DISCUSSION
The observed number of CVD deaths during 10 years of follow-up in Dutch men and women 
was overestimated by a factor 1.5–2 by SCORE-NL and by a factor 2 by SCORE-high, but 
was adequately predicted by SCORE-low. Applying SCORE-NL and especially SCORE-high 
can lead to pharmacological overtreatment. Nowadays, the SCORE function for low-risk 
regions fits best in the Dutch situation.
For this study, we used data from two monitoring projects with a large number of men and 
women (15,385 and 17,500 respectively). Risk factor data were measured with standardized 
methodology and mortality follow-up was almost complete. However, because of the 
decline in CVD mortality in the past decades in The Netherlands, the total number of CVD 
deaths during 10-year follow-up was low, especially among women. Even during a 10-year 
follow-up period we observed a two-fold higher CVD mortality rate in the cohort with 
respondents recruited between 1987 and 1992 compared with those recruited between 
1993 and 1997. Therefore, in the development and adaptation of risk charts based on 
national data, the period in which participants are recruited should be taken into account. 
The Dutch SCORE function published in 2006 was calibrated using risk factor data of the 
REGENBOOG-project.9 These risk factor data were collected more recently (1998–2001) 
than the ones in this study (1987–1997). The number of smokers was 1% lower in men and 6% 
in women, average blood pressure level was 7 mmHg higher in men and 6 mmHg in women, 
but serum total and HDL-cholesterol levels were similar (data provided by L. Viet, May 
2009). Baseline survival coefficients for the calibrated SCORE-NL function were derived 
from national CVD mortality statistics of 2000; whereas CVD mortality data in this study 
were collected between 1987 and 2007. Therefore, the national CVD mortality data are 
not representative for the entire follow-up period of our cohort. Furthermore, in contrast 
to this study, the national CVD mortality data were derived from the whole population 
including persons with pre-existing CVD. This could contribute to the discrepancy between 
the expected CVD mortality risk based on SCORE-NL and observed risk in this study.  
Similar studies, in which nationally adapted SCORE charts were evaluated in cohorts with 
a 10-year CVD mortality follow-up, have been published for the high-risk country, Sweden, 
and the low-risk country, Belgium.10,11 As in The Netherlands, also in Sweden, the calibrated 
SCORE risk function overestimated the number of CVD deaths, whereas in Belgium the 
calibrated function performed well. Both in Sweden and The Netherlands, CVD mortality 
has strongly declined in the past decades, whereas the decrease in Belgium was less 
pronounced.12,13 Thus, in countries with decreasing CVD mortality rates such as Sweden 
and The Netherlands, calibration removes only part of the overestimation. 
We also evaluated the performance of the SCORE-high and SCORE-low functions in The 
Netherlands and compared our results with those of other cohort studies with a 10-year 
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CVD mortality follow up. SCORE-high also overestimated the number of CVD deaths in 
the high-risk countries such as Iceland14 and Norway.15 As in The Netherlands, SCORE-low 
performed much better in Iceland and Norway. Again, the most important explanation 
for these overestimations of the number of CVD deaths in high risk countries are the 
strong decreasing CVD mortality trends in these countries.13 The consequence of these 
overestimations is, that persons who did not qualify for treatment based on SCORE-low 
will also be treated.  
The 2007 European guidelines on cardiovascular prevention recommended an absolute risk 
of 5% as cut-off point for treatment.2 According to the Framingham Study a 5% fatal CVD 
risk equals a 20% nonfatal and fatal CHD risk.16 The Dutch 2006 guideline proposed a cut-
off point of 10% fatal CVD risk for pharmacological treatment based on cost-effectiveness 
and a limited capacity of health care workers.3 As nowadays the number of persons with 
such a high risk is low, the European cut-off points might be reconsidered. However, all 
these cut-off points are arbitrary and in discussion; issues such as the balance between 
treatment and side effects, costs, health care capacity, and medicalisation also need to 
be considered. 
CONCLUSION
The results of this study show that overestimation of CVD mortality risk may result in 
pharmacological overtreatment. Therefore, SCORE risk functions need to be adapted 
regularly in countries where CVD mortality rates are changing, using recent risk factor and 
mortality data. Owing to the strongly improved survival of CVD patients, emphasis will 
shift from a focus on CVD mortality to morbidity. Therefore, new risk charts are needed 
based on both nonfatal and fatal CVD.3,14
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ABSTRACT
Aims: Body mass index (BMI) and waist circumference (WC) are both predictors of 
cardiovascular diseases (CVD). We compared absolute risk, hazard ratio (HR), and 
(population) attributable risk of nonfatal and fatal CVD for BMI and WC in a large 
prospective cohort study with an average follow-up of 10 years. 
Methods and results: Anthropometric data were measured between 1993 and 1997 in 
a general population sample of over 20,000 men and women aged 20–65 years in The 
Netherlands. All risks were adjusted for age and sex. Absolute risk of nonfatal CVD was 
on average 10 times higher than that of fatal CVD. In obese respondents (BMI ≥ 30 kg/
m2), relative risk of fatal CVD was four-fold higher [HR = 4.0 95% confidence interval (CI) 
= 2.4–6.6], whereas risk of nonfatal CVD was two-fold higher (HR = 1.8 95% CI = 1.6–2.2) 
than in normal weight respondents. Similar associations were observed for WC (≥ 88 vs. 
< 80 cm in women and ≥ 102 vs. 94 cm in men). In persons with overweight or obesity 
(BMI ≥ 25 kg/m2), half of all fatal CVD (attributable risk = 54%, 95% CI = 30–70) and a 
quarter of nonfatal CVD was ascribed to their overweight. On the population level, one-
third of all fatal CVD cases could be attributed to overweight and obesity (population 
attributable risk = 35%, 95% CI = 14–52), and about one in seven of nonfatal CVD cases.
Conclusion: The associations of BMI and WC with CVD risk were equally strong. 
Overweight and obesity had a stronger impact on fatal CVD than on nonfatal CVD.
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INTRODUCTION
Overweight and obesity are a major public health problem and contribute substantially 
to the burden of chronic diseases worldwide. Currently, more than 1.6 billion adults are 
overweight and at least 400 million are obese. In 2015, the number of overweight persons 
is expected to increase to 2.3 billion and the number of obese to 700 million.1 
Body mass index (BMI) and waist circumference (WC), a measure of abdominal obesity, 
are associated with risk factors for cardiovascular diseases (CVD)2-6 and are predictors of 
CVD mortality.7-11 As CVD mortality rates are strongly declining in Western countries,12,13 
the burden of CVD is nowadays more strongly determined by CVD morbidity. Therefore, 
information on the strength of the association of BMI and WC and on the contribution of 
overweight and obesity to the occurrence of nonfatal CVD is needed.14-16
Data on the associations of overweight and obesity with nonfatal CVD are mainly obtained 
from large prospective cohorts in which height and weight were self-reported and WC was 
self-measured.8,11,17,18 Visscher et al.19 showed that self-reported BMI data underestimate the 
true prevalence of obesity by at least 25%. For a correct estimation of the strength of the 
associations of BMI and WC with nonfatal and fatal CVD, anthropometric data measured 
by trained staff are needed.
In The Netherlands, in the Monitoring Project on Chronic Disease Risk Factors (MORGEN), 
cardiovascular risk factors were measured between 1993 and 1997 in a large cohort of 
over 20,500 respondents. We studied both BMI and WC in relation to absolute risk, hazard 
ratio (HR), attributable risk (AR), and population attributable risk (PAR) for 10-year fatal 
and nonfatal CVD.
METHODS
Study population 
In the MORGEN project, cardiovascular risk factor data were collected in about 20,500 
men and women aged 20-65 years during the period 1993-1997.20 The survey was carried 
out in a general population sample from the towns of Amsterdam (response rate 33%), 
Doetinchem (68%), and Maastricht (43%). The MORGEN project is one of the two Dutch 
cohorts participating in the European Prospective Investigation into Cancer and Nutrition 
(EPIC) project.7 The MORGEN project was approved by the Medical Ethics Committee 
of TNO Prevention and Health, Leiden and participants signed an informed consent 
form.
37
BM
I and w
aist circum
ference are both predictors of CVD
Chapter 3
Data collection
Body weight, height, and WC were measured according to the WHO recommendations21 
by trained staff. Body weight was measured to the nearest 100 g on calibrated scales. 
As participants were weighed wearing light indoor clothing (with empty pockets and no 
shoes), 1 kg was subtracted from the measured body weight. Height was measured to 
the nearest cm. Body mass index (BMI) was calculated by dividing weight (in kilograms) 
by height (in meters) squared. WC was measured at the level midway between the lower 
rib margin and the iliac crest at the end of gentle expiration, with participants in standing 
position. The mean of two measures was used for analysis. 
Nonfasting blood samples were taken and serum total cholesterol was measured by the 
CHOD-PAP method.22 HDL-cholesterol was determined in the supernatant after precipitation 
of apolipoprotein B-containing lipoproteins with magnesium phosphotungstate.23 All 
cholesterol determinations were done in a laboratory that is a permanent member of 
the international Cholesterol Reference Method Laboratory Network (Erasmus Medical 
Centre, Rotterdam, The Netherlands). 
Blood pressure was measured twice by a trained technician at the right upper arm with 
the participant in sitting position using a random zero sphygmomanometer. Systolic blood 
pressure was recorded at the first, and diastolic blood pressure at the fifth Korotkoff 
phase. The second measurement was carried out after counting resting heart rate for 
30s. The mean of both measurements was used in the analyses. 
Information on demographic variables, disease history, educational level, and lifestyle 
factors was obtained by standardized questionnaires. Smoking was dichotomized as 
‘current smoker’ or ‘non-smokers’. The prevalence of myocardial infarction and diabetes 
mellitus at baseline was based on self-report. Educational level was assessed at seven levels 
ranging from primary education or less to university education. For the present analyses 
education was divided into three categories: low (intermediate secondary education or 
less), medium (intermediate vocational or higher secondary education), or high (higher 
vocational or university education).
Nonfatal and fatal cardiovascular diseases 
Vita l status was checked through record linkage with the national population register. Only 
556 persons were lost to follow-up, of whom 538 persons emigrated. Data on fatal CVD 
were obtained from Statistics Netherlands (till 1 January 2006) and patients with nonfatal 
CVD were identified through linkage with the National Hospital Discharge Register (till 
1 January 2006). On the national level, 88% of the hospital admissions could be uniquely 
linked to a single person.24 Cases were censored at the date of the first hospital discharge 
or date of death. Other subjects were censored at the time of emigration or at the end 
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of follow-up (at a maximum of 11 years), with an average of 10 years. As this study was 
carried out in collaboration with the SCORE project, the same International Classification 
of Diseases (ICD) codes for nonfatal and fatal CVD25 were used: coronary heart disease (ICD 
9: 401–414, 798.1 and 798.2) and noncoronary CVD (ICD 9: 426–443; with the exception 
of 426.7, 429.0, 430.0, 432.1, 437.3, 437.4 and 437.5). After January 1996, corresponding 
ICD 10 codes were used for fatal CVD.
Data and statistical analyses
We excluded 242 persons with a self-reported history of myocardial infarction. In addition, 
we excluded 120 pregnant women, 44 persons with missing data on anthropometric 
measures, 161 persons with missing information on confounders, and the second record of 
48 persons measured twice. We also excluded 289 persons with a BMI of less than 18.5 kg/
m2. The remaining study population consisted of 9,062 men and 10,572 women. On account 
of the limited number of CVD deaths, we did not stratify for sex. There were no significant 
interactions with sex and age. Therefore, we combined data and adjusted for sex and age. 
Normal weight was defined as a BMI of 18.5–24.9 kg/m2, overweight as a BMI of 25–29.9 
kg/m2, and obesity as a BMI of 30 kg/m2 or more (WHO criteria). Cut-off points for WC for 
normal weight, overweight and abdominal obesity were defined in men at less than 94 
cm, 94–101.9 cm, and ≥ 102 cm, respectively, and in women at less than 80 cm, 80–87.9 
cm, and ≥ 88 cm, respectively.21,26 
Absolute risks (cumulative incidence rates during 10-years of follow-up) were calculated 
using general linear models, adjusted for sex and age. Associations of BMI and WC with 
risk of fatal and nonfatal CVD were analyzed with Cox proportional hazard models, 
adjusted for sex and age (model 1), sex, age, smoking behavior, and educational level 
(model 2) and additionally adjusted for systolic blood pressure, serum total cholesterol, 
HDL-cholesterol and self-reported diabetes mellitus (model 3). The proportionality of the 
hazards was verified by plotting the log-log survival curves and graphical inspection of 
parallelism of the curves. Data are presented as HR with confidence intervals (95% CI). 
Two-sided P-values of less than 0.05 were considered statistically significant.
The AR fraction in persons with obesity or who were overweight was calculated with 
the formula: AR = [HRov-1]/HRov, in which HRov = the hazard ratio in overweight or obese 
respondents versus normal weight respondents. The PAR for overweight and obesity was 
calculated with the formula: PAR = [Pov(HRov-1)]/ [Pov(HRov-1)+1],
27 in which Pov = proportion 
of overweight or obese persons in cohort and HRov = the hazard ratio of overweight or 
obese respondents versus normal weight respondents. The confidence intervals of the HRs 
for nonfatal and fatal CVD were applied to calculate the confidence intervals of the PARs.
For all analyses SAS 9.1 by SAS Institute Inc. (Cary, North Carolina, USA) 2002–2003 was used.
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RESULTS
On the basis of BMI, 42% of the men and 30% of the women were overweight, whereas 
10% of the men and 11% of the women were obese (Table 3.1). On the basis of WC (≥ 88 
cm in women and ≥ 102 cm in men), 19% of the men and 26% of the women had abdominal 
obesity. Obese persons smoked less, had a lower educational level, and more unfavorable 
CVD risk factor levels compared with persons with a healthy weight. BMI and WC were 
strongly correlated (Pearson’s r = 0.86 in men and r = 0.84 in women). During an average 
follow-up of 10 years, 728 men and 403 women were hospitalized for nonfatal CVD and 
81 men and 30 women died from CVD. 
In this cohort, with an average age of 43 years, the incidence of a first nonfatal CVD was 
approximately 10 times more frequent than that of fatal CVD (Figure 3.1). The absolute 
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Figure 3.1 Age- and sex-adjusted absolute 10-year nonfatal and fatal cardiovascular disease rates 
by BMI (kg/m2) and waist circumference (cm) category in men and women aged 20–65 years. 
WC categories: low: men < 94, women < 80 cm; medium: men 94–102 cm, women 80–88 cm; high: 
men ≥ 102 cm, women ≥ 88 cm. 
BMI, body mass index; CVD, cardiovascular disease; WC, waist circumference.
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risks of nonfatal and fatal CVD for categories of BMI as well as of WC were similar and the 
absolute risks increased from the normal weight category to the obesity category, with 
the largest increase from the overweight to the obesity category. 
For obesity, HR for fatal CVD adjusted for age and sex [BMI = 4.0 (2.4–6.6), WC = 2.9 
(1.8–4.7)] were approximately twice as strong as for nonfatal CVD [BMI = 1.8 (1.6–2.2), 
WC = 1.7 (1.5–1.9)] after adjustment for sex and age (Table 3.2). Adjustment for potential 
intermediate risk factors (systolic blood pressure, total cholesterol, HDL-cholesterol 
and self-reported diabetes mellitus), reduced the observed HR for fatal CVD by 50% and 
nonfatal CVD by 70% (Table 3.2).
In overweight or obese respondents, 53% of all fatal CVD (based on BMI or WC) and 22%–30% 
of nonfatal CVD (based on BMI respectively WC) is ascribed to their overweight (Table 
3.3). Given a prevalence of 46% for overweight and obesity in our population, 35% of all 
fatal CVD cases and 12%–17% (based on BMI respectively WC) of all nonfatal CVD cases can 
be attributed to overweight and obesity (Table 3.3).
DISCUSSION
In our population, the incidence of nonfatal CVD was on average 10 times higher than 
that of fatal CVD. Risk estimates for overweight were similar for BMI and WC. However, 
the strengths of the associations of obesity were approximately twice as strong for fatal 
compared with nonfatal CVD. Intermediate risk factors explained a large part of the 
association, especially for nonfatal CVD. One-third of all fatal CVD cases and about one-
seventh of all nonfatal CVD cases could be attributed to overweight and obesity.
Our cohort was relatively young (20–65 years) compared with other populations.10,11 As 
the relationship of BMI and WC with CVD mortality decreases with age,10,28 our findings 
may not be generalisable to older populations. 
Information on nonfatal CVD was obtained from hospital discharge data through linkage 
with the National Hospital Discharge Register. On a national level, 88% of the hospital 
admissions could be uniquely linked to a single person on basis of sex, date of birth and the 
numeric part of the postal code.24 Through this procedure, in 9% of the cases more than one 
person was merged to the same set of linkage variables and 4% could not be linked. Since 
almost all persons in the MORGEN-project had a unique combination of linkage variables 
and persons who emigrated were censored at the date of emigration, successful record 
linkage in our cohort was higher than 88%. Successful linkage was probably not related to 
BMI and WC, and we therefore believe that differential bias has not affected our findings. 
BMI and WC were strongly correlated in both men and women. The magnitude of the 
correlation was similar to that in other studies.7,8,11,14,29,30 A recent editorial concluded that 
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BMI and WC are similar indexes of body composition, which could explain the similar 
results for the associations of BMI and WC with all-cause mortality.31 This study extends 
this to the associations with nonfatal and fatal CVD.
Owing to the strongly improved survival of CVD patients in many Western countries,12,13 
the burden of CVD is nowadays strongly determined by CVD morbidity. Therefore it is 
important to establish the strength of the associations of BMI and WC with nonfatal 
CVD. We found a 10 times higher incidence of nonfatal CVD compared with fatal CVD 
in this relatively young cohort. This implies that only taking fatal CVD into account for 
risk prediction in individuals as assessed by e.g. SCORE risk charts,25 is only the tip of the 
iceberg, especially in young persons. 
We observed a four-fold increased risk of fatal CVD for obesity based on BMI and a three-
fold increased risk for obesity based on WC. These hazard ratios are higher than those 
reported by most other studies. In the EPIC project with 359,387 participants, that also 
included data of our cohort, the relative risks (RR) from circulatory causes of death (ICD 10 
codes I00–I99) were similar for BMI and WC categories,7 but they were lower than those 
in this study (in EPIC men: HR = 1.6 for BMI and HR = 1.8 for WC; in EPIC women: HR = 1.3 
for BMI and HR = 2.3 for WC). Men and women in EPIC were on average 10 years older. 
Furthermore, in this study, the HR in older respondents of our cohort (40–65 years) was 
lower than that in respondents aged 20–40 years (HR = 3.2 and HR = 12.5, respectively for 
BMI; HR = 2.8 and HR = 3.4, respectively for WC), but this could not completely explain 
the difference with EPIC. 
In the large prospective study collaboration (PSC) with almost 1 million persons at risk 
with subsequently about 30,000 vascular deaths during an average follow-up of 8 years 
(deaths in first 5 years excluded), obese persons (BMI 30–35 vs. 22.5–25 kg/m2) had a 
two-fold risk of ischemic heart disease, stroke or other vascular diseases in the 35–59 
years age group (web table 10). Although the age range of the PSC study is comparable 
with the present study and in most studies BMI was measured, RR for vascular deaths 
was lower. In studies with self-reported anthropometric data, RRs are generally lower for 
BMI as well as WC (range RR 1.6–2.7),8,11,32 except in the Health Professionals Follow-up 
Study (RR = 3.9 for obesity based on BMI and HR = 2.9 based on WC in men aged 40-64 
years).10 These lower risks are very likely the result of underreporting of body weight and 
overreporting of height, especially in overweight persons,19 leading to attenuation of the 
relationship between obesity and CVD. In most epidemiological studies with incident CVD 
as an endpoint, data were presented for the combined endpoint of nonfatal and fatal 
CVD. RRs of nonfatal and fatal CVD of 1.5–2 were observed for obesity based on either 
BMI or WC.15,17,18,29 These findings are in line with the results of this study for nonfatal CVD.
In the present study, adjustment for the intermediate classical CVD risk factors (systolic 
blood pressure, total-cholesterol and HDL-cholesterol and self-reported diabetes) 
44
Chapter 3 BMI and waist circumference are both predictors of CVD
explained about 70% of the association of obesity based on BMI or WC with nonfatal 
CVD and 50% of the association with fatal CVD. In a meta-analysis of 21 cohort studies, 
about 45% of the increased risk of fatal or fatal and nonfatal CHD events in overweight 
and obese persons was explained by higher blood pressure and cholesterol levels.33 
The results of these studies suggest that major CVD risk factors explain the increased 
CVD risk caused by obesity by about 50%. The results of this study suggest that the 
intermediate CVD risk factors explain even a larger part of the occurrence of nonfatal 
CVD risk caused by obesity. 
In this relatively young cohort, in overweight or obese respondents, half of all fatal 
CVD and a quarter of nonfatal CVD was ascribed to their overweight. On the population 
level, one-third of all fatal CVD cases and one in seven of all nonfatal CVD cases could 
be attributed to overweight and obesity. The impact of overweight and obesity on fatal 
CVD for BMI is two times and for WC three times stronger than the impact on nonfatal 
CVD. Overweight and obesity explain the occurrence of fatal CVD to a large extent than 
that of nonfatal CVD.
We conclude that in adults aged 20–65 years, the burden of CVD is changing from fatal 
to nonfatal cardiovascular diseases. For overweight and obesity based on BMI as well as 
on WC, similar associations were obtained for nonfatal and fatal CVD. These associations 
were approximately twice as strong for fatal than for nonfatal CVD. Especially for 
nonfatal CVD, the impact of obesity was to a large extent attributable to intermediate 
risk factors. One out of three of fatal and one out of seven of nonfatal CVD cases can be 
attributed to overweight and obesity in the population. This emphasizes the importance 
of overweight prevention in CVD prevention. Measuring overweight has the advantage 
that it does not require medical investigations and can be based on self-identification 
by persons at risk.
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ABSTRACT
Background: A positive parental history of myocardial infarction (MI) is an independent 
risk factor for cardiovascular diseases (CVD). However, different definitions of parental 
history have been used. We evaluated the impact of parental gender and age of onset 
of MI on CVD incidence. 
Methods: Baseline data were collected between 1993 and 1997 in 10,524 respondents 
aged 40-65 years. CVD events were obtained from the National Hospital Discharge 
Register and Statistics Netherlands. We used proportional hazard models to calculate 
hazard ratios (HR) and 95% confidence intervals (CI) for CVD incidence and adjusted 
for lifestyle and biological risk factors.
Results: At baseline, 36% had a parental history of MI. During 10-year follow-up, 914 
CVD events occurred. The age and gender adjusted HR was 1.3 (95% CI 1.1-1.5) for those 
with a paternal MI, 1.5 (1.2-1.8) for those with a maternal MI and 1.6 (1.2-2.2) for those 
with both parents with an MI. With decreasing parental age of MI, HR increased from 
1.2 (1.0-1.6) for age ≥ 70 years to 1.5 (1.2-1.8) for age < 60 years for a paternal MI and 
from 1.1 (0.9-1.5) to 2.2 (1.6-3.0) for a maternal MI. The impact of having a mother with 
MI before age 60 significantly differed in women [2.9 (1.8-4.6)] and men [1.5 (0.9-2.6)]. 
Adjustment only slightly influenced HRs for maternal MI.
Conclusions: Respondents with a parental history of MI have an increased CVD 
incidence, in particular with parental onset of MI before age 70. A maternal history of 
MI before age 60 was the strongest predictor of CVD incidence.
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INTRODUCTION
A positive parental history of a myocardial infarction (MI) is an independent risk factor 
for cardiovascular diseases (CVD). This relationship was already demonstrated in the 
1970s in men1 and in the 1980s in women,2 and has been confirmed in many prospective 
studies. However, most studies were conducted in men only and parental history was not 
uniformly defined. Simple definitions were used as having a parent, a father or a mother, 
or both parents with a history of MI, regardless of the age of onset. Relative risks of 1.0-2.2 
in men and women were found.3-13 Some studies showed a slightly stronger paternal4,12,13 
and others a stronger maternal transmission3,5,6,9 in men. In women, only a few studies 
were conducted.6,8,9 For both parents with a history of MI, regardless of the age of onset, 
a relative risk of approximately 2 was observed.6
In most studies on the risk of premature parental MI, the cut-off for the age of onset of the 
MI was fixed and ranged from a parental MI before the age of 65 to before age 50.1,5,9,14-17 
The National Cholesterol Education Program Third Adult Treatment Panel (NCEP ATP III) 
recommended that cut-off points should be age of onset before age 65 in the father and 
before age 55 in the mother.18 These different cut points for men and women were applied 
in several studies.19-21 Relative risks of premature parental history of MI amounted to 1.2-
2.8 in men and women. As for parental history irrespective of age of onset, differences 
between paternal and maternal transmission were inconsistent, and for those with both 
parents who had had a premature MI, relative risks of 1.5-4.1 were found.4,16,21,22
The age of onset of MI was studied in more detail in two large US cohorts.6,22 These studies 
showed a continuous increase in relative risks of CVD with decreasing paternal or maternal 
age of onset of the MI. In men, a paternal and maternal MI before age 706,22 conferred a 
greater risk of CVD (RR 1.7-2.6) compared to those with a higher parental age of MI. For 
women this was the case for a paternal and maternal MI below age 50.6  
An important question is, whether the positive relationship between parental history 
of MI can be explained by lifestyle factors such as smoking, alcohol intake and physical 
inactivity and/or risk factors such as blood pressure and serum cholesterol. In most studies, 
adjusting for lifestyle4,5,6 and risk factors14,15,16,19-21 only slightly lowered the relative risk in 
respondents with (premature) parental MI. 
The aim of the present study was to investigate the relationship between various 
definitions of parental history of MI and CVD incidence in the offspring, with emphasis 
on the impact of a maternal and paternal MI and on older or younger parental age of 
onset of the MI. Furthermore we investigated the impact of lifestyle and risk factors on 
the association between parental history and CVD incidence.
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METHODS
Study population 
In the Monitoring Project on Chronic Disease Risk Factors (MORGEN-project), baseline 
cardiovascular risk factor data were collected in 1993-1997 in about 23,000 men and 
women aged 20-65 years.23,24 The project was carried out in random population samples 
of Amsterdam, Maastricht and Doetinchem in the Netherlands. We used only data of 
respondents aged 40-65 years, because many younger respondents will have parents 
who were too young to have experienced an MI. The survey was approved by the Medical 
Ethics Committee of TNO Prevention and Health, Leiden and respondents signed an 
informed consent form.
Data collection
Information on parental history of MI, demographic variables, lifestyle factors, educational 
level and disease history was obtained by standardized questionnaires. Parental history 
of MI was ascertained using the questions ‘did your father ever experience an MI’ and 
‘did your mother ever experience an MI’, followed by a question about the age of onset 
for those reporting a parental MI. We categorized respondents into four categories 
of parental history: both parents without MI (reference group), a father only with 
MI, a mother only with MI or both parents with MI. In order to study the effect of age 
of onset of MI, and to define premature MI, the age of onset of the parental MI was 
classified as ≥ 70 years, 60-69 years and < 60 years for both the mother and the father. 
In a reproducibility study in part of our respondents, 75% of respondents were classified 
into the same parental history group again (no, one or two parents with MI < 60 years in 
men and < 65 years in women). Smoking was dichotomized as ‘current smoker’ or ‘non-
smokers’ (including ex-smokers). Alcohol consumption was defined as none, moderate 
(male: ≤ 2 glasses/female ≤ 1 glass per day) and high (male: > 2 glasses/female > 1 glass 
per day). Physical activity was assessed by a validated questionnaire in respondents 
recruited between 1994 and 1997. For this subset, we calculated whether respondents 
practised cycling and sports with a metabolic equivalent score ≥ 4 (yes/no).25 Educational 
level was classified into three categories: low (intermediate secondary education or less), 
intermediate (intermediate vocational or higher secondary education) or high (higher 
vocational or university education). The prevalence of MI or diabetes mellitus at baseline 
(yes/no) was based on self-report. 
Body weight and height were measured by trained staff according to the WHO 
recommendations. BMI was calculated by dividing weight (in kg) by height (in m) squared.26 
Non-fasting blood samples were taken and serum total cholesterol was measured by the 
CHOD-PAP method. HDL-cholesterol was determined in the supernatant after precipitation 
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of apo B-containing lipoproteins with magnesium phosphotungstate.27 All cholesterol 
determinations were done in a standardized laboratory.23 Blood pressure was measured 
twice by a trained technician at the right upper arm with the participant in sitting position 
using a random zero sphygmomanometer. Systolic blood pressure was recorded at 
the first, and diastolic blood pressure at the fifth Korotkoff phase. The mean of both 
measurements was used in the analyses.
Mortality and morbidity follow-up 
The cohort was linked to three registries. Vital status was checked by the national 
population register. Data on CVD mortality during follow-up were obtained from Statistics 
Netherlands (till 1 January 2006). CVD morbidity was identified through linkage with the 
National Hospital Discharge Register (till 1 January 2006) based on information on the date 
of birth, gender and postal code using a validated probabilistic method.24 Total CVD was 
defined as the first event during 10-year follow-up, either nonfatal or fatal, whichever came 
first. Cases were censored at the first date of hospital admission for CVD or at the date of 
death. Other subjects were censored at the date of emigration, date of death, at the end of 
follow-up or at a maximum of 11 years, resulting in a mean follow-up of 10 years. We defined 
fatal and nonfatal events identical to the ICD-codes used in the SCORE-project: CVD (ICD 
9: 401-414, 426-443, 798.1, 789.2, ICD 10: I10-I25, I46, I47-I51, I61-I65, G45, I67-I69, I70-I72, 
R96).28 In total, 914 events occurred, of which 40 were fatal without a previous nonfatal 
event. Most events were due to coronary heart diseases (557), peripheral arterial diseases 
(128), stroke (125), heart failure (60) and hypertensive ischemic heart diseases (40).
Data and statistical analyses
We excluded respondents without informed consent for linkage with registries, 
respondents under the age of 40, prevalent cases of MI and respondents with missing 
data on parental history of MI and age of onset, on lifestyle and risk factors. This left 10,524 
respondents, 4,878 men and 5,646 women for analysis. First we investigated whether 
there was interaction between gender and parental history of MI. Since there was no 
significant interaction (p = 0.22) for most definitions of parental history of MI, we pooled 
the data of men and women and adjusted for gender. There was interaction with gender 
only for those respondents whose mother had an MI before age 60 (p = 0.04). 
Baseline characteristics of the study population by parental MI – subdivided by paternal, 
maternal or both parents with MI – were described as mean and standard deviation for 
normally distributed continuous variables and numbers and percentages for categorical 
variables. The 10-year cumulative incidence rates according to parental history of MI were 
calculated. 
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Associations between parental history of MI and CVD incidence were analyzed with Cox 
proportional hazard models. The proportionality of the hazards was verified by plotting 
the log-log survival curves and graphical inspection of parallelism of the curves. In all 
analyses respondents with ‘both parents without an MI’ were used as the reference 
category. All hazard ratios (HR) were adjusted for age and gender. The HR’s for maternal 
MI were stratified by gender, adjusted for paternal MI and included an interaction term 
mother*gender in the model. We additionally adjusted for education and the following 
lifestyle-related factors: current smoking status, alcohol intake and BMI. In the main 
analyses we did not adjust for physical activity because this variable was not estimated 
in respondents recruited in 1993 and adjustment for physical activity in the respondents 
recruited from 1994-1997 only slightly attenuated the HRs. Furthermore, we adjusted for 
the risk factors serum total and HDL-cholesterol, systolic blood pressure (continuously) 
and for self-reported diabetes mellitus (dichotomously).
For all analyses SAS 9.2 by SAS Institute Inc. (Cary, North Carolina, USA ) 2002-2008 was 
used.
RESULTS
At baseline, 36% of the men and women had one or two parents who experienced an MI 
(23% only a father with MI, 8% only a mother with MI and 4% both parents) (Table 4.1). 
Age of respondent was not associated with parental history of MI, while average systolic 
blood pressure and serum total cholesterol and the prevalence of self-reported diabetes 
were highest in those with two parents with an MI. The number of current smokers was 
lowest in men with two parents with an MI. A high level of education was more common in 
respondents with parents without MI and those with a father with MI. Fathers experienced 
their MI at a mean age of 63, mothers at age 67. 
All three groups with a positive parental history of MI had an increased CVD risk compared 
to those without a parental history of MI (Table 4.2, Figure 4.1). The age and gender 
adjusted pooled HR was 1.3 (95% CI 1.1-1.5) for having only a father, 1.5 (1.2-1.8) for having 
only a mother and 1.6 (1.2-2.2) for having both parents with MI. With decreasing parental 
age of MI, the HR for a paternal MI increased from 1.2 (1.0-1.6) for age ≥ 70 years to 1.5 
(1.2-1.8) for age < 60 years and for a maternal MI from 1.1 (0.9-1.5) to 2.2 (1.6-3.0). 
No interaction between gender and parental history of MI was found, except an interaction 
between gender and maternal history of MI at age below 60 (p = 0.04). Compared to 
women without a parental history of MI, the HR was 1.0 (0.6-1.6) for women having a 
mother with age of onset of MI above 70 years, 1.9 (1.2-3.1) at age 60-69 years and 2.9 
(1.8-4.6) at age below 60 (Figure 4.2). Compared to men without a parental history of MI, 
these HRs were 1.2 (0.8-1.7), 1.6 (1.0-2.5) and 1.5 (0.9-2.6) respectively in men. 
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Figure 4.1 Hazard ratio of CVD and 95% confi dence intervals, adjusted for age and gender in 
respondents aged 40-65 years by parental age of onset of MI.
Figure 4.2 Age and father’s age of onset of MI adjusted hazard ratio of CVD and 95% confi dence 
intervals in men and women aged 40-65 years by mother’s age of onset of MI.
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In multivariable analyses - adjusting for age, gender, education and lifestyle-related factors 
such as smoking, physical activity (in subset), alcohol intake and BMI - HRs for paternal MI 
were of the same magnitude compared to those adjusted only for age and gender, and 
slightly lower for maternal MI. Additional adjustment for biological risk factors yielded 
similar HRs for paternal MI and slightly attenuated the HRs for maternal MI at age of onset 
below 60 years (Table 4.2).
DISCUSSION
Respondents with a parental history of MI had a 30-60% higher CVD risk, after adjustment 
for age and gender, regardless of the age at which their parents had an MI. In cases of 
premature parental MI (defined as onset of MI before age 70), a maternal transmission 
of CVD risk was twice as strong (80-120% increased risk) as paternal transmission (40-50%). 
The impact of a maternal MI at age below 60 was twice as strong as in women (HR 2.9) 
than in men (HR 1.5). These associations could not be explained by higher levels of lifestyle 
and biological risk factors in respondents with a paternal history of MI and only to a small 
extent in those with a maternal history of MI. 
The strength of the present study was that we had detailed information on parental history 
of MI for men and women. The vast majority of studies on the relationship of parental 
history of MI with CVD incidence reported on men only. We did not find an interaction 
between gender and parental history of MI, so our data suggest that results did not differ 
between men and women. We had also information available on the age of onset of MI in 
both fathers and mothers. Only a few studies investigated parental MI according to the age 
of onset of parental MI and CVD incidence beyond cut-off points for premature history of 
MI.6,22 We reported on respondents aged 40-65 years, because younger respondents had 
parents who were too young to have experienced an MI. However, even in the selected 
age group of respondents, some parents were too young to have experienced an MI, 
especially mothers. Mean age of MI in mothers was four years lower than in fathers. 
Information on nonfatal CVD was obtained from hospital discharge data through record 
linkage with the National Hospital Discharge Register. The linkage success rate for 
cardiovascular endpoints was 97.6%.24 Comparison of hospital discharge diagnoses for a 
sub sample from the Maastricht area with a cardiology information system in this region, 
showed that 14.2% of the cases of acute myocardial infarction were not registered in the 
hospital discharge register.29 The reliability of the cause-of-death coding was examined 
by Statistics Netherlands. The inter-coder agreement of the underlying cause of death by 
ICD-10 code was 89.1% for acute myocardial infarction and 78.5% for stroke.30 This minor 
underestimation and misclassification of nonfatal and fatal endpoints probably did not 
affect the association between parental history of MI and CVD incidence. 
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We studied the impact of parental history of MI on nonfatal and fatal CVD incidence. 
This broad endpoint definition was the same as the one used in the SCORE-project28 and 
included myocardial infarction (21%), angina pectoris (20%), cerebrovascular accidents 
(14%), peripheral arterial diseases (14%), congestive heart failure (7%) and hypertensive 
heart diseases (4%). Similar broad definitions of CVD were also used in some studies,6,14,21 
while almost all studies included nonfatal and fatal CHD.5,9,12,13,16,22 However, similar relative 
risks were observed for parental history of MI in relation to different definitions of CVD 
endpoints, suggesting similar impacts on CHD and CVD incidence. 
As in most studies, in the present study parental history of MI was based on self-report by 
the respondents. We only conducted a reproducibility study and found a 75% agreement. 
Several validation studies were carried out by others, in which parental events were 
confirmed by medical records.31-33 Parental history of MI or CHD was correctly reported 
by 68%-89% of respondents. In the Framingham Heart Study, in which both off-spring 
and parental CVD events were validated, higher relative risks for a parental history of MI 
were found.21 This suggests that stronger relative risks are obtained when more accurate 
information on parental history of MI is used. 
Our results confirm previous findings of an independent relationship between parental 
history of MI and CVD incidence. For the ‘simple’ definitions of having a father, a mother 
or both parents with a history of MI, we found HRs of 1.3, 1.5 and 1.6 respectively, 
which were in the same order of magnitude as observed in other studies (RR 1.2-2.2).3-13 
Furthermore, we showed a strong gradient of CVD incidence with decreasing parental 
age of onset of MI. CVD incidence was significantly increased when a father or a mother 
experienced an MI under the age of 70. This cut-off point of a premature parental history 
of MI was comparable to that found in US Physicians’ Health and Health Professionals 
studies6,22 However, the cut-off points for increased CHD risk set by the NCEP expert 
panel (fathers who were younger than 65 at the age of onset and mothers who were 
under 55 at the age of onset)18 and the fixed cut-off points used in most other studies for 
premature parental MI (at or before the age of 65)1,9,14-16,21 are at younger age compared 
to the present study, especially those for women. We observed a stronger maternal 
than paternal transmission of risk for different ages of onset of an MI. However, other 
studies on (premature) parental MI found either a stronger paternal transmission,4,7,12,15,16 
stronger maternal transmission3,5,6,9 or no difference21,22 in men. So definitive conclusions 
cannot be drawn on this issue.
In the present study, adjusting for education, lifestyle and risk factors did not influence 
the CVD incidence for paternal MI, and only sli ghtly attenuated the CVD incidence 
associated with maternal MI. Similar results were found in other studies on lifestyle4-6 and 
risk factors5,14-17,19-21 This means that the relationship between a positive family history and 
CVD incidence is largely independent from known lifestyle and risk factors. Therefore, this 
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relationship may be due to genetic factors. However, influence of unknown or unmeasured 
lifestyle and biological factors cannot be excluded.
In conclusion, individuals with a parental history of MI had an increased CVD incidence 
of similar magnitude in men and women. CVD risk increased gradually with decreasing 
parental age of onset of MI. Based on our results, a premature parental MI can be defined 
as having a father and/or a mother with MI before the age of 70. Higher age cut-off points 
for defining premature parental MI might be warranted. The strongest associations were 
observed in persons with a mother who had an MI before age 60, especially in women. 
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ABSTRACT
Aims: European physicians use SCORE risk charts to predict a patient’s 10-year risk of 
cardiovascular disease (CVD) mortality. We examined whether the inclusion of nonfatal 
events improved risk prediction and the identification of high risk persons. 
Methods and results: In the EPIC-NL cohort, risk factor data were collected between 
1993 and 1997 in 6,772 men and 9,108 women aged 35-65 years. During 10 years 
of follow-up, 540 total (fatal + nonfatal) CVD events occurred, of which 122 (23%) 
were fatal. Risk equations were developed using Cox proportional hazard models. 
Discriminating ability and hazard ratios for CVD risk factors did not differ between the 
two endpoints. Absolute risks for total CVD were approximately four times higher than 
for CVD mortality. Using the current 5% CVD mortality threshold or the 20% total CVD 
threshold for identification of high risk persons leaves more than 84% of all male and 
98% of all female future cases untreated. Of those exceeding these thresholds, 20% and 
27% of the men, respectively, and 16% and 19% of women will experience a CVD event 
in the next 10 years. Cut-off points of 2% for CVD mortality, corresponding to 10% for 
total CVD, will identify high-risk persons of whom approximately 10% will experience a 
CVD event in the next 10 years.
Conclusion: CVD mortality comprises a quarter of all total CVD events. Risk functions and 
the discriminating ability did not differ between the two endpoints. Cut-off points of 2% 
for CVD mortality or 10% for total CVD could be considered to identify high-risk persons. 
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INTRODUCTION
In 1994, the first Task Force of the European Societies of Cardiology, Atherosclerosis 
and Hypertension recommended the estimation of coronary heart disease (CHD) risk 
based on the Framingham risk charts for CHD prevention in clinical practice. They advised 
intensive treatment of all risk factors when the absolute 10-year risk of nonfatal and fatal 
CHD exceeded 20%.1 However, in several European countries the Framingham risk charts 
overestimated CHD risk, potentially leading to overtreatment.2,3 
In 2003, the third Joint European Societies Task Force on cardiovascular disease (CVD) 
prevention introduced risk charts of the SCORE (Systematic COronary Risk Evaluation) 
project.4,5 The SCORE risk charts were derived from a large database of prospective studies 
including over 200,000 persons in Europe. These charts predicted 10-year CVD mortality 
risk, whereas the previously used Framingham risk charts predicted both fatal and nonfatal 
CHD events. Consequently, the cut-off point for increased risk was changed,  from ≥ 20% 
previously used in Framingham charts for incident CHD1,6-8 to ≥ 5% for CVD mortality in the 
SCORE risk charts.4,5,9 
Risk charts predicting CVD mortality do not reflect the total burden of CVD.10 In high 
income countries, CVD mortality rates are continuously decreasing,11 which might be 
interpreted as an indication that CVD is no longer an important public health problem.12 
However, low CVD mortality is accompanied by a high incidence of nonfatal CVD.13 
Therefore, a change in risk prediction from CVD mortality to total (fatal plus nonfatal) 
CVD  has been advocated.4,9,14  
In 2008, an updated Framingham Heart Study general CVD risk function was developed 
with an expanded CVD endpoint.10 The threshold previously used for high CHD risk (≥ 
20% in 10 years, ATP III guidelines7) is now used for total CVD.6,8,10 The 2011 Guideline of 
the American Heart Association for CVD prevention in women recommended a cut-off 
point of ≥ 10% for high total CVD risk.15 Based on recent analyses of clinical trials the 
American Heart Association concluded that generic statins are already cost-effective 
at this threshold.15
The purpose of this article is to investigate the effect of including nonfatal events in 
the equation used for cardiovascular risk prediction, on identifying high-risk persons. 
We evaluated also the discriminating ability of a risk function based on either CVD 
mortality or total CVD, and the implications of a change from CVD mortality to total 
CVD for the identification of high-risk persons eligible for drug treatment in clinical 
practice. 
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SUBJECTS AND METHODS
Study population and data collection 
We used data from the EPIC-NL study, consisting of the two Dutch cohorts (MORGEN 
and PROSPECT) that comprise the Dutch contribution to the European EPIC study. These 
cohorts started separately in 1993-1997 and were later merged into the EPIC-NL-cohort.16 
For the present analysis, data of participants aged 35-65 years at baseline were used. 
We excluded 5,579 persons aged < 35 years, 2,576 women aged > 65 years, 605 patients 
with a history of myocardial infarction, stroke or heart failure based on self-report or 
hospital discharge data, and those with missing data on smoking, serum total and HDL 
cholesterol or systolic blood pressure. In total, 6,772 men and 9,108 women were included 
in the analysis. All participants provided informed consent before they were included in 
the study. The study complies with the Declaration of Helsinki and was approved by two 
medical ethics committees.
Vital status of EPIC-NL participants was obtained through record linkage with the municipal 
population registries. Data on morbidity were obtained from the National Medical 
Registry (NMR), a digital database of hospital discharge diagnoses (until 1 January, 2006). 
In the NMR all diagnoses were coded according to the 9th revision of the International 
Classification of Diseases (ICD). The EPIC-NL cohort was linked to the NMR using a validated 
probabilistic method.17 Causes of death were obtained through linkage with ‘Statistics 
Netherlands’ (follow-up completed until 1 January, 2006). ICD-9 codes were used until 1 
January, 1996, and corresponding ICD-10 codes thereafter. Cases were censored at the 
first date of hospital admission for CVD, the date of death or emigration, or at the end of 
follow-up (at a maximum of 11 years), whichever came first. Loss to follow-up was less 
than 2% among respondents who gave informed consent.16
CVD mortality and total CVD
We defined fatal CVD events identical to the ICD codes used in the SCORE-project, ICD-9: 
401-414, 426-443, 798.1 and 798.2. After January 1996 corresponding ICD-10 codes were 
used. For nonfatal CVD we included nonfatal acute myocardial infarction, stroke and heart 
failure (ICD-9 codes: 410, 427.5, 428, 430, 431, 433, and 436). 
The reliability of the cause of death coding was examined by Statistics Netherlands. The 
inter-coder-agreement of the underlying cause of death by ICD-10 code was 89% for MI, 79% 
for stroke and 76% for heart failure.18 The success rate for linking nonfatal cardiovascular 
events was 98%.16 Comparison of hospital discharge diagnoses with diagnoses from a 
cardiology information system showed a sensitivity of 84% for myocardial infarction and 
43% for heart failure.19
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Data analysis 
We defined total CVD as fatal plus nonfatal CVD. A case of fatal or nonfatal CVD could 
only be included once and was censored at the time of a first nonfatal event or death, 
whichever came first. The observed 10-year cumulative incidence rates were calculated 
for CVD mortality and total CVD. Subsequently we calculated the ratio of the observed 
total CVD to CVD mortality and 95% confidence intervals (CI). 
To estimate 10-year CVD mortality risk we used the risk function composed for the 
Netherlands (SCORE-NL) by the SCORE-group20 and published in the Dutch Clinical 
Guideline on Cardiovascular Risk Management.21 We used the following basic risk 
function: 
CVD risk = 1-Survivalbaseline*exp[β1*gender + β2*age + β3*smoking status + 
β4*(systolic blood pressure – mean SBP) + β5 *(ln ratio total/HDL-cholesterol – 
mean ln ratio)]. 
Cox regression was used to estimate the betas for each endpoint as well as the baseline 
survival function. For the two endpoints, baseline survival was used to estimate the 10-
year risk of a 35-year-old, non-smoking woman. We assessed the statistical significance 
of interactions between the classical risk factors and gender. As the interaction terms 
were not statistically significant, we fitted a single model for both men and women. 
Subsequently, we tested whether the coefficients for the risk factors differed between 
the two risk prediction functions.22
The risk discriminating ability, a measure to distinguish future cases from noncases, was 
expressed as the Area Under the ROC-curve (AUROC) including a 95%-confidence interval 
(CI). The AUROC ranks persons according to their risk. Future cases were the observed 
fatal plus nonfatal CVD cases. An AUROC of 0.5 means no discrimination, 0.7 acceptable 
discrimination and 1.0 perfect discrimination.23  
We also cross-tabulated different categories of risk predicted by the model with CVD 
mortality as endpoint against a broader range of risk categories predicted by the model 
with total CVD as endpoint. We calculated the proportion of future cases among those at 
high risk and eligible for drug treatment, using the European 5% CVD mortality treatment 
thresholds,4,9 the US Framingham 20% global CVD treatment thresholds10 and, for women, 
the recently proposed American Heart Association treatment thresholds of 10%.15 We 
defined corresponding thresholds for CVD mortality and total CVD for identification of 
similar proportions of 10% future CVD cases among those at high risk.
For all analyses SAS 9.2 (SAS Institute Inc., Cary, North Carolina, USA) 2002-2008 was 
used.
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RESULTS
This study included 15,880 persons, of whom 43% were men (Table 5.1). Men had, on 
average, a 5 mmHg higher SBP, and a 0.3 mmol/l lower HDL-cholesterol level than women 
(Table 5.1). During, on average, 10 years of follow-up approximately twice as many men 
experienced a CVD event as women. The ratio of observed total CVD to CVD mortality 
was 4.0 (95% CI 3.4-5.0) in men and 5.2 (95% CI 4.1-7.2) in women. 
In Table 5.2, the hazard ratios and 95% CIs for the risk factors included in the models 
predicting 10-year risk of CVD mortality and total CVD, respectively, are presented for men 
and women combined. These hazard ratios were similar for CVD mortality and total CVD. 
The area under the ROC curve was of the same magnitude for CVD mortality and total 
CVD, suggesting that the discrimination between future cases and non-cases did not differ 
between the risk function for CVD mortality and the function for total CVD (Figure 5.1). 
In Table 5.3, the risk categories of CVD mortality are cross-tabulated against the risk 
categories of total CVD. Absolute risk levels for total CVD were approximately four fold 
higher than absolute risk levels for CVD mortality. Using the 5% CVD mortality threshold, 
of the 224 men with this high risk, 50 (22%) developed a CVD event during the next10 years 
(Table 5.3A). Using the 20% total CVD threshold, 31 (27%) out of 119 men developed an 
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Table 5.1 Baseline risk factor levels (1993-1997), and 10-year fatal and total CVD, in Dutch men and 
women aged 35-65 years, without a history of CVD (MORGEN cohort)
Values are mean (SD) for continuous variables. HDL, high-density lipoprotein; CVD, cardiovascular diseases.
1Fatal CVD: ICD-9: 401-414, 426-443, ICD-10: I10-I25, I46, I47-I51, I61-I65, G45, I67-I69, I70-I72, R96.
2Total CVD: fatal CVD codes + nonfatal myocardial infarction, stroke and heart failure (ICD-9 codes: 410, 427.5, 
428, 430, 431, 433, 436).
Men
(n = 6,772)
Women
(n = 9,108)
Age (years) 48.2 (7.4) 49.2 (7.6)
Systolic blood pressure (mmHg) 127 (16) 122 (18)
Serum total cholesterol (mmol/l) 5.5 (1.0) 5.5 (1.0)
Serum HDL-cholesterol (mmol/l) 1.2 (0.3) 1.5 (0.4)
Serum total-to-HDL-cholesterol ratio 5.0 (1.7) 3.9 (1.2)
Body mass index (kg/m2) 26.0 (3.5) 25.3 (4.3)
Smokers (%) 34 34
Fatal CVD1 cases 80 (1.2%) 42 (0.5%)
Total CVD2 cases 321 (4.7%) 219 (2.4%)
event. Using the 10% total CVD threshold, 116 (13%) events occurred in 871 high risk men. 
This corresponded to 156 (12%) CVD events in 1,314 men with a CVD mortality risk of 2% or 
higher. During 10 years of follow-up, 84% of all future CVD cases among men occurred below 
the 5% CVD mortality threshold and 49% below the 2% CVD mortality threshold (Table 5.3A). 
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Table 5.2 Hazard ratios (95% confi dence intervals) for 10-year risk of CVD mortality and total CVD 
in Dutch men and women combined, aged 35-65 years
SBP, systolic blood pressure; HDL, high density lipoprotein.
*P-value for the diﬀ erence between the hazard ratios for CVD mortality and total CVD.
CVD mortality Total CVD P-value*
Male gender 2.14 (1.45-3.18) 1.65 (1.37-1.98) 0.22
Age, per 10 years 2.30 (1.73-3.04) 1.93 (1.70-2.20) 0.16
Smoking (y/n) 2.17 (1.52-3.12) 1.99 (1.68-2.40) 0.59
SBP, per 20 mmHg 1.61 (1.35-1.92) 1.47 (1.35-1.61) 0.60
Serum total-to-HDL cholesterol, per unit 2.75 (1.56-4.87) 2.78 (2.11-3.62) 0.68
Figure 5.1 Receiver Operating Characteristics (ROC) curves for 10-year CVD mortality and total CVD 
in Dutch men and women of the MORGEN cohort. — CVD mortality (AUROC 0.7457); – – Total CVD 
(AUROC 0.7472).
70
Chapter 5 Including nonfatal events in CVD risk prediction
Table 5.3 Classifi cation of the observed total CVD cases according to predicted risk of CVD 
mortality by risk of total CVD in men (A) and women (B)
All, cases + non-cases.
(A) men
Risk of total CVD
Risk of CVD 
mortality
0-3% 3-5% 5-7% 7-10% 10-20% ≥ 20% Total Ratio all/
cases
0-2% Cases (n)
All (n)
37         
2,537
42     
1,630
59
974
27      
317 1,756
165
5,458
33
2-3% Cases (n)
All (n)
1
10
39
428  
12
188
52
626
12
3-4% Cases (n)
All (n) 5
37
310
37
315
9
4-5% Cases (n)
All (n)
17
149
17
149
9
≥ 5% Cases (n)
All (n)
19
105
31
119
50
224
4
Total Cases (n)
All (n)
37         
2,537
42     
1,630
60
984
66
750
85
752
31
119
321
6,772
21
Ratio All/ 
cases
69 39 16 11 9 4 21
(B) women
Risk of total CVD
Risk of CVD 
mortality
0-3% 3-5% 5-7% 7-10% 10-20% ≥ 20% Total Ratio all/
cases
0-2% Cases (n)
All (n)
89         
6,417
48      
1,479
31
612
15      
232
183      
8,740
48
2-3% Cases (n)
All (n)
10        
136
9          
84
19        
220
12
3-4% Cases (n)
All (n)
9        
87
9        
87
10
4-5% Cases (n)
All (n)
3          
29 1
3         
30
10
≥ 5% Cases (n)
All (n)
1          
11
4
20
5         
31
6
Total Cases (n)
All (n)
89         
6,417
48      
1,479
31
612
25
368
22
211
4
21
219      
9,108
42
Ratio All/
cases
72 31 20 15 10 5 42
Using the 5% CVD mortality threshold, during 10 years of follow-up, of the 31 women with 
this high risk, 5 (16%) developed a CVD event during the next 10 years (Table 5.3B). Using 
the 20% total CVD threshold, 4 (19%) out of 21 women experienced an event. Using the 
10% total CVD threshold, 26 (11%) events occurred in 232 high risk women. This percentage 
corresponded to 36 (10%) CVD events in 368 women with a CVD mortality risk of 2% or 
higher. In women, 98% of all future CVD cases occurred below the 5% CVD mortality 
threshold and 84% below the 2% CVD mortality threshold (Table 5.3B).
DISCUSSION
In the EPIC-NL cohort of middle-aged persons, about a quarter of all total CVD events 
were fatal events. The strengths of the associations of the risk factors did not differ 
between the models predicting CVD mortality and total CVD. Also the models for the 
two endpoints discriminated equally well between future CVD cases and non-cases. The 
currently used cut-off point of 5% for CVD mortality leaves a very large proportion of future 
cases untreated. When using a cut-off point of 2% for CVD mortality, or 10% for total CVD, 
similar proportions of 10% of future cases in high-risk men and women will be identified.
To the best of our knowledge, this is the first prospective study that provides insight 
into how total CVD relates to CVD mortality. Older studies reported on CHD only and 
did not distinguish between first and recurrent events.24,25 In several primary prevention 
trials the ratio of total to fatal major cardiovascular events varied between 3.2 and 4.5 
(WOSCOPS, JUPITER and CARDS).26 These trials included slightly older age groups, and 
only a few women. The ratio of 4 in men in our middle-aged population-based sample is 
in line with these data.  
In the present study, the relationships between risk factors and CVD mortality did not differ 
significantly from their relationship with total CVD. Similar results were obtained in other 
prospective cohort studies using CHD as endpoint.5 The two equations also discriminated 
equally well between future CVD cases and non-cases. Other studies did not compare 
risk discrimination between future CVD cases and non-cases in models with these two 
endpoints. The AUROC for predicting CVD mortality risk in the SCORE data set was 0.763 
in men and 0.807 in women.27,28 In our study the AUROC for CVD mortality was 0.749 in 
men and 0.710 in women. An explanation for the different results in the two studies could 
be that the AUROCs for men and women in the SCORE study were based on risk factor 
data collected in the 1970s and 1980s, when the absolute CVD mortality risk was higher 
than in the present study, in which risk factor data were collected around 1995. 
Risk prediction tools and guidelines for CVD risk assessment use different definitions of 
CVD endpoints.14,27,29 Thresholds for drug treatment depend on the diseases included in the 
definition of nonfatal CVD events.5 The updated Framingham risk score included a broad 
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range of CVD endpoints, e.g. angina pectoris and peripheral vascular disease.6,10 Since risk 
tables are used to identify high risk persons who will benefit from drug treatment, we 
included only vascular diseases such as non-fatal myocardial infarction, stroke and heart 
failure for which there is sufficient evidence that blood pressure and cholesterol lowering 
will reduce the number of CVD events.26,30,31 
Any threshold for defining high-risk persons is arbitrary, but necessary for decision-making 
in clinical practice. In current European guidelines, intensive treatment is recommended 
for CVD mortality risk ≥ 5%.4,9 In US guidelines predicting total CVD or global CVD risk, 
cut-points for drug treatment were set at ≥ 20%.6,10 In the present study, within the group 
exceeding the 5% threshold for CVD mortality and the corresponding threshold of 20% for 
total CVD, approximately 20% of the men and women developed a CVD event. Only a small 
number of persons had such a high risk. These cut-off points leave a large proportion of 
high-risk persons untreated. If the threshold of 10% for total CVD, as recommended by 
the American Heart Association for women,15 will  be used for both women and men, still 
1 in 10 of these high-risk persons would develop a fatal or nonfatal event in the next 10 
years. To decide whether or not this 10% total CVD threshold, or the equivalent threshold 
of 2% CVD mortality, could be used, not only depends on the level of risk, but also on the 
results of cost-effectiveness analyses. 
We conclude that about a quarter of total CVD is due to fatal events. To discriminate 
between future CVD cases, the risk function predicting CVD mortality performed as well 
as the risk function predicting total CVD. Both the 5% CVD mortality threshold and the 20% 
total CVD threshold for high risk leaves a very large number of persons untreated. The 
present study showed that cut-off points of 2% for CVD mortality and 10% for total CVD 
identify high-risk persons of whom approximately 10% will develop a CVD event in 10 years. 
With such a high yield of cases that can be adequately treated with blood pressure and 
cholesterol lowering drugs, consideration should be given to lowering the thresholds for 
treatment which are currently in use.
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ABSTRACT
Background: In clinical practice, individuals at increased risk of cardiovascular diseases 
(CVD) are identified on the basis of age, sex, smoking status, blood pressure and serum 
total and HDL-cholesterol. We examined whether CVD risk prediction improved when 
obesity (BMI ≥ 30 kg/m2) and premature (< 70 y) parental myocardial infarction (MI) 
were added to the classical risk factor model. 
Methods: Risk factors were measured in 1993-1997 in 12,818 participants (53% female) 
aged 35-65 in the Dutch MORGEN project. Cases of fatal and nonfatal CVD during 10 
years of follow-up were identified through record linkage. Classical risk factor equations, 
obtained by Cox proportional hazard analysis, were extended with obesity, paternal 
MI and maternal MI. We calculated the Net Reclassification Index (NRI), a measure for 
correct reclassification of subjects, to check improvement in risk prediction using 5% 
and 10% increments in absolute CVD risk.
Results: A CVD event occurred in 280 men and 140 women. Obesity and maternal MI 
were positively and significantly related to total CVD after adjustment for classical risk 
factors (both hazard ratios ~1.5). Adding obesity and parental MI to CVD risk prediction 
yielded a significant NRI of 4.5% in men and a non-significant NRI of 2.6% in women when 
5% risk categories were used. For 10% categories, the NRIs were slightly larger (5.5% and 
3.3%, respectively). The improvements in risk prediction were mainly due to obesity.
Conclusion: Modest improvements in CVD risk prediction can be obtained when obesity 
and, to a lesser extent, parental MI were added to the risk function. 
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INTRODUCTION
European guidelines on cardiovascular disease (CVD) prevention in clinical practice 
recommend individual risk assessment based on classical risk factors (CRF), such as 
smoking status, blood pressure, and serum cholesterol.1 Persons at high risk are eligible 
for intensive treatment, both pharmacological and lifestyle. Although CVD risk increases 
exponentially, cut-off points are needed for treatment decisions in clinical practice. From 
a cost-effectiveness perspective, it is necessary to optimise ranking of persons according 
to their risk and, if possible, to limit the use of laboratory measurements.2 
There is great interest in improving risk prediction by adding additional risk factors to 
the classical models.2-6 Models have been extended with risk factors such as heart rate, 
educational level, body mass index (BMI), family history of myocardial infarction (MI), 
C-Reactive Protein and fibrinogen, and measures of atherosclerosis such as carotid intima-
media thickness.3-6,7 These risk factors are generally independently associated with the 
occurrence of CVD. Traditionally, the added value of incorporating new risk factors into 
CRF models was evaluated by measuring the improvement in risk discrimination by the 
Area Under the Receiver Operating Characteristics Curve (AUROC). However, additional 
risk factors hardly improve risk discrimination beyond the CRF models.4,8 A new and more 
relevant method to evaluate improvement in risk prediction in clinical practice, is the net 
reclassification index (NRI).8 This measure provides information on reclassification of 
persons to more appropriate CVD risk categories.5,8 The NRI depends on the thresholds 
chosen for the risk categories.8 
In Europe, risk prediction is frequently based on the European Systematic COronary Risk 
Evaluation (SCORE) equations.9 These models include age, sex, smoking status, systolic 
blood pressure, and serum total and HDL-cholesterol. Obesity and parental history of MI 
are not included, although these are easy to measure risk factors, which do not require 
laboratory measurements.7,9 Obesity, defined as a BMI ≥ 30 kg/m2, is an independent 
predictor of CVD risk.10-14 Since the SCORE risk function does not include diabetes, obesity 
may add to improve risk prediction. So far, for treatment decisions, obesity is considered 
as an additional risk factor, but is not included in most risk prediction equations.2,7 The 
reason that obesity is not included in CRF models in the US, is that BMI did not or only 
slightly improved CVD risk discrimination.15,16 
Parental history of MI is also an independent risk factor, but associations may differ for 
paternal and maternal MI.17 Information on this risk factor can easily been obtained by 
asking whether the father or the mother experienced an MI before a certain age. Parental 
history of premature MI or CVD is incorporated in several risk score systems.7,18-20 However, 
to the best of our knowledge, there is no information available on improvement of risk 
prediction by adding parental history of MI alone to a model containing the SCORE classical 
risk factors.  
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The SCORE risk models predict 10-year risk of CVD mortality. However, CVD mortality 
does not reflect the total burden of CVD.21 In high income countries, CVD mortality 
rates are continuously decreasing,22 but a low CVD mortality is accompanied by a high 
incidence of CVD.23 Therefore, a change in risk prediction from CVD mortality to total 
(fatal plus nonfatal) CVD has been advocated.1-3 In 2008, an updated Framingham Heart 
Study general CVD risk function was developed with an expanded CVD endpoint and a 
cut-off point for high total CVD risk of ≥ 20% in 10 years was used.4,21 The 2011 Guideline 
of the American Heart Association for CVD prevention in women recommended a lower 
cut-off point for total CVD risk of ≥ 10%.24 Although BMI and parental MI have been added 
to CHD risk prediction models,5 they were not added to models with CVD endpoints and 
evaluated by the NRI.
In the present study we assessed how obesity and parental MI relate to total CVD risk, and 
examined whether inclusion of these factors in the CRF model improved risk prediction. 
METHODS
Study population 
In the Monitoring Project on Chronic Disease Risk Factors (MORGEN project), baseline 
cardiovascular risk factor data were collected between 1993 and 1997 in about 23,000 
men and women aged 20-65 years.25,26 The project was carried out in random population 
samples of Amsterdam, Maastricht and Doetinchem in the Netherlands. The study was 
approved by the medical ethics committee of TNO Prevention and Health, Leiden, and 
respondents signed an informed consent form.
Data collection
Information on demographic variables, smoking status, parental history of MI and disease 
history was obtained by standardised questionnaires.25 Smoking was dichotomised 
into ‘current smoker’ or ‘non-smoker’ (including ex-smokers). Parental history of MI 
was assessed using the questions ‘did your father ever experience an MI’ and ‘did your 
mother ever experience an MI’, followed by a question about the age of onset for those 
reporting a parental MI. We found in an earlier study that parental history of MI before 
age 70 independently predicted total CVD.27 Therefore we defined premature MI as having 
a father and/or a mother with MI before age 70.
Body weight and height were measured by trained staff according to the WHO 
recommendations. BMI was calculated as weight (in kilograms) divided by height (in 
metres) squared. Obesity was defined as a BMI of 30 kg/m2 or higher, based on WHO criteria. 
We excluded persons with a BMI < 18.5 kg/m2. Non-fasting blood samples were taken and 
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serum total cholesterol was measured by the CHOD-PAP method. HDL-cholesterol was 
determined in the supernatant after precipitation of apo B-containing lipoproteins with 
magnesium phosphotungstate. All cholesterol determinations were done in a certified 
laboratory.25 Blood pressure was measured twice by a trained technician at the right upper 
arm with the participant in sitting position using a random zero sphygmomanometer. 
Systolic blood pressure (SBP) was recorded at the first Korotkoff phase. The mean of 
both measurements was used in the analyses.
Mortality and morbidity follow-up 
Vital status was checked through record linkage with the national population register. 
Data on CVD mortality during follow-up were obtained from Statistics Netherlands. CVD 
morbidity was identified through linkage with the National Hospital Discharge Register, 
using a validated probabilistic method.26 Follow-up was completed until 1 January, 2006. 
Total CVD was defined as the first event during 10-year follow-up, either nonfatal or fatal. 
Cases were censored at the date of first hospital admission for CVD, the date of death or 
emigration, or at the end of follow-up. 
CVD mortality was defined as in the SCORE project according to the International 
Classification of Diseases (ICD) 9th revision (401-414, 426-443, 798.1 and 798.2) or 10th 
revision (I10-I25, I46-I51, I61-I65, G45, I67-I72 and R96).9 CVD morbidity included nonfatal 
MI, stroke and heart failure (ICD-9 codes 410, 427.5, 428, 430, 431, 433, 434 and 436). 
This definition of nonfatal CVD was used by the Dutch Working Group on Revision of the 
Guidelines for Cardiovascular Risk Management of 2006,28 and includes only those forms 
of CVD for which sufficient evidence exists that in high-risk individuals the risk can be 
reduced by antihypertensive and/or cholesterol lowering treatment.
Data analysis 
We selected 7,746 men and 8,968 women aged 35-65 years and subsequently excluded 
respondents without informed consent for linkage with registries (< 5%), without successful 
record linkage (< 2%), prevalent cases of MI, stroke or heart failure, and respondents with 
missing risk factor data, leaving 5,967 men and 6,851 women for statistical analyses. 
To estimate 10-year risk of CVD, we used the basic risk function prepared for the 
Netherlands (SCORE-NL) by the SCORE-group29 and published in the Dutch Clinical Guideline 
on Cardiovascular Risk Management.28 This function included the classical risk factors for 
CVD: age, sex, smoking status, SBP and the ratio of total/HDL-cholesterol. This model was 
subsequently extended with dummy variables for obesity, and/or paternal and maternal 
MI. Cox proportional hazard models were used to estimate the regression coefficients for 
all risk factors. Baseline survivals were calculated for a non-smoking woman aged 35 years, 
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without obesity and/or parental MI. We present the hazard ratios (HRs) with confidence 
intervals (95% CI) for the risk factors included in the different models, and tested whether 
these HRs differed.30 Ten-year estimated risk of total CVD was categorised using 5% cut-off 
values (0-<5%, 5-<10% , ≥ 10%), or 10% cut-off values (0-<10%, 10-<20% and ≥ 20%).
The performance of the different models was assessed by the NRI, with positive values 
indicating correct reclassification.8 Respondents with a CVD event and those without a CVD 
event (non-events) were classified according to their estimated CVD risk. Risk categories based 
on the classical risk factors and the extended models were cross-tabulated, after which the 
NRI was calculated. Basically, the NRI shows the improvement in risk prediction by taking the 
‘net’ proportion of events (more correctly) reclassified into a higher risk category, minus the 
‘net’ proportion of nonevents (incorrectly) reclassified in a higher risk category. Significance 
was tested assuming independence between events and nonevents (z > 1.96) with the null 
hypothesis of NRI = 0. We calculated the NRI both for 5% and 10% risk cut-off values. For all 
analyses SAS 9.2 (SAS Institute Inc., Cary, North Carolina, USA) 2002-2008 was used.
RESULTS
The study comprised 12,818 subjects (53% female) with a mean age of 48 ± 7 years at baseline 
(Table 6.1). Mean risk factor levels were similar in men and women, except for a lower SBP 
and a higher HDL-cholesterol level in women. BMI ≥ 30 kg/m2 was present in 11% of the 
men and 12% of the women. The percentage of respondents with a father or mother who 
suffered from an MI before age 70 was 20% and 6%, respectively. During 10-year follow 
up, 280 men (4.7%) and 140 women (2.0%) experienced a fatal or nonfatal CVD event. 
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Table 6.1 Baseline risk factor levels in 12,818 Dutch men and women aged 35-65 years without a 
history of myocardial infarction, stroke or heart failure
Values are mean (SD) or percentages.
BMI, body mass index; HDL, high-density lipoprotein; MI, myocardial infarction; Obesity, BMI ≥ 30 kg/m2.
Men 
(n = 5,967)
Women 
(n = 6,851)
Age (y) 48.0 (7.4) 48.9 (7.4)
Systolic blood pressure (mmHg) 127 (16) 120 (17)
Serum total cholesterol (mmol/l) 5.5 (1.0) 5.5 (1.0)
Serum HDL-cholesterol (mmol/l) 1.2 (0.3) 1.5 (0.4)
Total/HDL cholesterol ratio 5.0 (1.7) 3.8 (1.2)
Current smokers (%) 34 34
BMI (kg/m2) 25.9 (3.4) 25.3 (4.1)
Obesity (%) 11.1 12.2
Maternal MI < 70 y (%) 5.0 7.3
Paternal MI < 70 y (%) 20.9 19.0
Approximately a quarter of the total CVD cases in men and a fifth in women were fatal. 
Obesity and maternal MI were independent predictors of total CVD (Table 6.2). The HR 
of 1.2 for a paternal MI was not statistically significant. Adding obesity, and/or paternal 
and maternal MI to the CRF model did not change the HRs of the risk factors (Table 6.2).
Using the CRF model and categorising CVD risk in 5% categories, 10-year estimated CVD 
risk increased from 1.9% for the risk category of 0-5% risk to 12.6% for the category ≥ 10% 
in men, and from 1.5% to 12.3% in women, respectively. Extending the CRF model with 
obesity resulted in a NRI of 2.2% in men and 1.1% in women (Table 6.3A). Extending the 
CRF model with paternal MI and maternal MI also improved risk prediction in men (2.5%) 
but not in women (-0.7%). Including both risk factors improved risk prediction by 4.5% in 
men (significant) and 2.6% in women. 
Using the CRF model and categorising CVD risk in 10% categories, 10-year estimated CVD 
risk increased from 3.5% for the risk category of 0-10% to 23.4% for the risk category ≥ 20% 
in men, and from 1.9% for the risk category of 0-10% to 13.2% for the risk category of 10-20% 
in women. Only 8 women had an estimated CVD risk ≥ 20%, but none of them actually 
experienced an event during follow-up. Extending the CRF model with obesity resulted 
in a NRI of 3.8% in men (significant) and 2.7% in women. Extending the CRF model with 
parental MI improved risk prediction by 2.0% in men and 0.6% in women (Table 6.3B). 
After adding both risk factors, risk prediction improved by 5.5% in men (significant) and 
3.3% in women.
More detailed information on reclassification of CVD events and non-events by extending 
the CRF model with obesity and/or parental MI is provided in Appendix 6.1.
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Table 6.2 Hazard ratios for total CVD during 10 years of follow-up, using a classical risk factor 
model (CRF) and CRF models extended with obesity and parental MI
CVD, cardiovascular diseases; SBP, systolic blood pressure; MI, myocardial infarction. 
*BMI ≥ 30 kg/m2 vs BMI 18.5-30 kg/m2; **Both maternal MI and paternal MI are included in the model.
Hazard ratio (95% confidence interval)
CRF model CRF model 
with obesity*
CRF model 
with parental 
MI**
CRF model 
with obesity and 
parental MI**
Male gender 1.71 (1.38-2.12) 1.79 (1.44-2.22) 1.74 (1.41-2.16) 1.82 (1.47-2.26)
Age (per 10 years) 1.95 (1.69-2.25) 1.96 (1.70-2.27) 1.97 (1.71-2.28) 1.99 (1.72-2.30)
Smoking (y/n) 1.91 (1.57-2.32) 1.96 (1.61-2.38) 1.90 (1.56-2.31) 1.95 (1.61-2.37)
SBP (per 20 mmHg) 1.49 (1.35-1.65) 1.44 (1.30-1.60) 1.48 (1.34-1.64) 1.43 (1.29-1.59)
Total/HDL cholesterol ratio 
(per unit) 
2.85 (2.11-3.86) 2.61 (1.91-3.55) 2.77 (2.04-3.74) 2.53 (1.86-3.45)
Obesity (y/n)* 1.52 (1.19-1.93) 1.51 (1.19-1.93)
Maternal MI < 70 y (y/n)
Paternal MI < 70 y (y/n)
1.45 (1.03-2.03)
1.17 (0.93-1.48)
1.44 (1.03-2.02)
1.18 (0.93-1.48)
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DISCUSSION
In the present study, obesity and maternal MI were independent risk factors for total CVD 
in both men and women. In men, obesity, but not parental MI significantly improved risk 
prediction (at 10% increments in CVD risk). An additive effect of obesity and parental MI 
was found and together they improved risk prediction strongest (at 5% and 10% increments 
in CVD risk). In women, no significant improvements in risk prediction were obtained after 
adding obesity and/or parental MI to the risk function. 
In the present study, obesity is an independent risk factor of total CVD and obese persons 
had a 50% higher CVD risk compared to non-obese persons.  In a large prospective cohort 
study,12 and in meta-analyses of  prospective studies11,16 similar or slightly higher risks were 
found. These higher risks were adjusted for age, sex and smoking status only, but became 
lower when adjustments were made for intermediate risk factors, e.g. systolic blood 
pressure and total cholesterol.16 In the present study, relative risks for obese persons 
with a BMI ≥ 30 kg/m2 were calculated with non-obese persons as reference category 
(BMI 18.5-30 kg/m2). In other studies, relative risks of obese persons with BMI 30-35 kg/
m2 were compared with lower BMI values as reference category (e.g. BMI 23.5-25 kg/m2). 
These differences might explain the lower relative risks observed in the present study. 
Adding obesity to a model including similar risk factors as the SCORE model improved 
risk classification significantly by 3.8% in men (10% increments in CVD risk). No other 
publications reported on the NRI of adding obesity to the CRF model. However, in a 
subset of about 50,000 men and women from pooled data of 58 studies (58% from 
Europe, 56% women), adding BMI (per SD) to the Framingham risk factor model, did not 
improve risk prediction of CVD (NRI = -0.19%, p = 0.5; risk categories < 5%, 5-10%, 10-20% 
and ≥ 20%).16 A similar analysis of our data, also showed a non-significant improvement 
in NRI in men and women. These results suggest that a proper operationalisation of BMI 
is essential. When a continuous analysis is done expressing BMI per SD, the NRI did not 
improve. However the NRI improved, when the BMI was dichotomised in those who 
were, or were not obese.
A positive family or parental history of premature MI, is generally defined as a parent 
who experienced an event before age 60. Many prospective studies have shown that 
a positive family history is an independent risk factor of CVD in men and women.17 We 
found in our population that the definition of premature family history could be extended 
to an event before age 70.27 A maternal MI before age 70 increased CVD risk by 40% and 
a paternal history of MI increased CVD risk by 20%. The literature is inconsistent on the 
specific effects of maternal and paternal history of MI on CVD.17,27,31,32 Therefore, we included 
both maternal and paternal history of MI in our risk function, although the latter was not 
statistically significant. 
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We are not aware of other studies that calculated the NRI for adding a positive family 
history only to a CRF model. Ridker et al. included a positive family history together with 
C-Reactive Protein into a CRF model.6 They found an improvement in the NRI of 5.3% 
in men. In other studies, adding CRP alone to the Framingham CRF model, improved 
correct risk classification by 3%-9%, depending on the thresholds of the risk categories.33 
Therefore, we conclude that only modest improvements of the NRI can be expected of 
adding parental history to CRF models.    
The improvements in risk prediction by adding obesity and parental MI to the CRF model 
were not significant in women. Although our cohort consisted of a large number of women, 
their absolute CVD risk was very low. In the CRF model, 98% of the women had a CVD risk 
between 0 and 10% and in 0.1% CVD risk was ≥ 20%. Using the 5% increments in CVD risk, still 
90% of the women had a risk between 0 and 5% and only 2% exceeded risk of 10% and higher, 
the new cut-off point for high CVD risk in women, proposed in the 2011 American Heart 
Association guideline for CVD prevention.24 In case of both the 5% and 10% increments in CVD 
risk, only a few women could potentially have moved to a higher risk category and this is 
the most likely explanation for the observation that adding these two risk factors did not 
improve the NRI. Cohorts with more events are needed before statements can be made 
about the effect of these additional factors on the correct classification of high-risk women.
In general, the NRI depends on the choice of cut-off points.8 A threshold for defining 
persons at low, intermediate and high risk is arbitrary, but necessary for clinical decision 
making. In men the 5% and 10% increments in CVD risk, provided similar improvements in 
risk prediction by adding obesity and parental history of MI to the CRF model (NRI = 4.5% 
at 5% and 5.5% at 10% risk categories). However, risk improvement by adding obesity alone 
attenuated when the 5% risk categories were used instead of the 10% risk categories. This 
suggests that adding obesity to the CRF model is meaningful for risk prediction in men at 
highest risk.
To the best of our knowledge, the present study is the first to show that adding obesity to 
the CRF model modestly improved risk prediction in men. Risk prediction improved further 
when parental history of MI was added to the model, although the impact of the latter risk 
factor was not statistically significant in itself. Risk prediction in women did not improve. 
Using 5% instead of 10% increments in absolute CVD risk, leads to similar conclusions. 
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APPENDIX 6.1 
Reclassification of CVD events and non-events, and net reclassification index (NRI) for a classical 
risk factors model (CRF) and models extended with obesity and parental MI, using increments of 
5% (A) and 10% (B) in absolute CVD risk. 
CVD, cardiovascular diseases; CRF, classical risk factors; MI, myocardial infarction; NRI, net 
reclassification index. Both maternal and paternal MI are included in the model.
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A. Men , risk categories 0-5%, 5-10% and ≥ 10%
Men CRF model with obesity 
CRF model 0-5% 5-10% ≥ 10% Total Number up Number down
Events
0-5% 66 4 0 70
5-10% 5 94 14 113
≥ 10% 0 7 90 97
Total 71 105 104 280 18 12
Non-events
0-5% 3,521 117 0 3,638
5-10% 122 1,171 84 1,377
≥ 10% 0 84 588 672
Total 3,643 1,372 672 5,687 201 206
NRI = (18/280 – 12/280) – (201/5,687 – 206/5,687) = 0.022 (z = 1.122, P-value = 0.26).
Men CRF model with parental MI 
CRF model 0-5% 5-10% ≥ 10% Total Number up Number down
Events
0-5% 66 4 0 70
5-10% 3 103 7 113
≥ 10% 0 2 95 97
Total 69 109 102 280 11 5
Non-events
0-5% 3,536 102 0 3,638
5-10% 110 1,211 56 1,377
≥ 10% 0 67 605 672
Total 3,646 1,380 661 5,687 158 177
NRI = (11/280 – 5/280) – (158/5,687 – 177/5,687) = 0.025 (z = 1.691, P-value = 0.091).
Men CRF model with obesity and 
parental MI
CRF model 0-5% 5-10% ≥ 10% Total Number up Number down
Events
0-5% 63 7 0 70
5-10% 7 89 17 113
≥ 10% 0 6 91 97
Total 70 102 108 280 24 13
Non-events
0-5% 3,471 166 1 3,638
5-10% 183 1,091 103 1,377
≥ 10% 0 120 552 672
Total 3,654 1,377 656 5,687 270 303
NRI = (24/280 – 13/280) – (270/5,687 – 303/5,687) = 0.045 (z = 2.037, P-value = 0.042).
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A. Women, risk categories 0-5%, 5-10% and ≥ 10%
Women CRF model with obesity 
CRF model 0-5% 5-10% ≥ 10% Total Number up Number down
Events
0-5% 93 2 0 95
5-10% 4 20 6 30
≥ 10% 0 2 13 15
Total 97 24 19 140 8 6
Non-events
0-5% 5,962 102 0 6,064
5-10% 93 414 33 540
≥ 10% 0 21 86 107
Total 6,055 537 119 6,711 135 114
NRI = (8/140 – 6/140) – (135/6,711 – 114/6,711) = 0.0112 (z = 0.416, P-value = 0.68).
Women CRF model with parental MI
CRF model 0-5% 5-10% ≥ 10% Total Number up Number down
Events
0-5% 92 3 0 95
5-10% 4 25 1 30
≥ 10% 0 1 14 15
Total 96 29 15 140 4 5
Non-events
0-5% 6,002 62 0 6,064
5-10% 67 454 19 540
≥ 10% 0 15 92 107
Total 6,069 531 111 6,711 81 82
NRI = (4/140 – 5/140) – (81/6.711 – 82/6.711) = - 0.0077 (z = -0.361, P-value = 0.72).
Women CRF model with obesity and 
parental MI
CRF model 0-5% 5-10% ≥ 10% Total Number up Number down
Events
0-5% 90 5 0 95
5-10% 5 17 8 30
≥ 10% 0 4 11 15
Total 95 26 19 140 13 9
Non-events
0-5% 5,936 128 0 6,064
5-10% 122 375 43 540
≥ 10% 0 33 74 107
Total 6,058 536 117 6,711 171 155
NRI = (13/140 – 9/140) – (171/6,711 – 155/6,711) = 0.026 (z = 0.779, P-value = 0.44).
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B. Men, risk categories 0-10%, 10-20% and ≥ 20%
Men CRF model with obesity 
CRF model 0-10% 10-20% ≥ 20% Total Number up Number down
Events
0-10% 169 14 0 183
10-20% 7 59 6 72
≥ 20% 0 2 23 25
Total 176 75 29 280 20 9
Non-events
0-10% 4,931 84 0 5,015
10-20% 84 483 23 590
≥ 20% 0 17 65 82
Total 5,015 584 88 5,687 107 101
NRI = (20/280 – 9/280) – (107/5,687 – 101/5,687)= 0.0382 (z=1.970, P-value = 0.049).
Men CRF model with parental MI 
CRF model 0-10% 10-20% ≥ 20% Total Number up Number down
Events
0-10% 176 7 0 183
10-20% 2 69 1 72
≥ 20% 0 1 24 25
Total 178 77 25 280 8 3
Non-events
0-10% 4,959 56 0 5,015
10-20% 67 515 8 590
≥ 20% 0 8 74 82
Total 5,026 579 82 5,687 64 75
NRI = (8/280 – 3/280) – (64/5,687 – 75/5,687) = 0.020 (z = 1.645, P-value = 0.10).
Men CRF model with obesity and 
parental MI
CRF model 0-10% 10-20% ≥ 20% Total Number up Number down
Events
0-10% 166 17 0 183
10-20% 6 59 7 72
≥ 20% 0 3 22 25
Total 172 79 29 280 24 9
Non-events
0-10% 4,911 104 0 5,015
10-20% 120 439 31 590
≥ 20% 0 14 68 82
Total 5,031 557 99 5,687 135 134
NRI = (24/280 – 9/280) – (135/5,687 – 134/5,687) = 0.0533 (z = 2.577, P-value = 0.010).
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B. Women, risk categories 0-10%, 10-20% and ≥ 20%
Women CRF model with obesity 
CRF model 0-10% 10-20% ≥ 20% Total Number up Number down
Events
0-10% 19 6 0 125
10-20% 2 13 0 15
≥ 20% 0 0 0 0
Total 120 20 0 140 6 2
Non-events
0-10% 6,571 33 0 6,604
10-20% 21 74 4 99
≥ 20% 0 3 5 8
Total 6,592 110 9 6,711 37 24
NRI = (6/140 – 2/140) – (37/6,711 – 24/6,711) = 0.0266 (z = 1.316, P-value = 0.19).
Women CRF model with parental MI 
CRF model 0-10% 10-20% ≥ 20% Total Number up Number down
Events
0-10% 124 1 0 125
10-20% 1 13 1 15
≥ 20% 0 0 0 0
Total 125 14 1 140 2 1
Non-events
0-10% 6,585 9 0 6,604
10-20% 15 81 3 99
≥ 20% 0 1 7 8
Total 6,600 101 10 6,711 22 16
NRI = (2/140 – 1/140) – (22/6.711 – 16/6.711) = 0.0062 (z = 0.504, P-value = 0.62).
Women CRF model with obesity and 
parental MI
CRF model 0-10% 10-20% ≥ 20% Total Number up Number down
Events
0-10% 117 8 0 125
10-20% 4 10 1 15
≥ 20% 0 0 0 0
Total 121 18 1 140 9 4
Non-events
0-10% 6,561 43 0 6,604
10-20% 33 59 7 99
≥ 20% 0 2 6 8
Total 6,594 104 13 6,711 50 35
NRI = (9/140 – 9/140) – (50/6,711 – 35/6,711) = 0.0334 (z = 1.298, P-value = 0.20).
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General discussion 
7
In the second part of the 20th century, major risk factors for developing cardiovascular 
diseases (CVD) were identified.1 Risk factors, such as age, sex, smoking, high blood 
pressure, hyperlipidaemia and diabetes are now widely accepted.2 The first risk charts and 
multivariable risk prediction functions that included these risk factors were constructed 
in the 1970s in the USA, based on the Framingham Heart Study.3 The risk charts intended 
to aid clinicians in assessing patients’ risk of developing coronary heart disease (CHD) and 
facilitate treatment decisions.1,2 The Framingham risk charts were introduced in Europe 
with the 1994 Guidelines on the prevention of CHD in clinical practice.4 Since these charts 
overestimated CHD risk in several European countries,5,6 the SCORE (Systematic COronary 
Risk Evaluation) risk charts were introduced in 2003.7 Persons with an estimated 10-year risk 
of CVD mortality of 5% or more were called high risk, and were eligible for pharmacological 
treatment. The SCORE risk charts have been implemented in clinical practice in many 
European countries, including the Netherlands.
In the past 30 years, unifactorial treatment of hypertension or hypercholesterolaemia 
shifted towards integrated cardiovascular risk management. The first – Framingham based 
– risk charts were introduced in the Netherlands in the 1998 Cholesterol Consensus8 and 
the 2000 Guideline on high blood pressure.9 Three years after the European guidelines, a 
nationally adapted SCORE risk chart was introduced in the 2006 Guideline on Cardiovascular 
Risk Management (CVRM).10 Furthermore, a web-based HEART SCORE calculator became 
available.11 However, it was not known how well the underlying risk functions fitted the 
Dutch situation. These SCORE risk functions predicted CVD mortality risk. Although CVD 
mortality rates in the Netherlands are continuously decreasing, a low CVD mortality 
is accompanied by a high nonfatal CVD incidence (Figure 7.1).12,13 Therefore, clinicians 
requested a change in risk prediction from CVD mortality to total (fatal plus nonfatal) CVD. 
Pharmacological treatment of high levels of blood pressure or serum cholesterol were 
recommended for high-risk persons, and for those with an intermediate risk combined with 
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Figure 7.1 Trends in standardised CVD mortality and CVD hospital admissions in the Netherlands 
per 100,000. Year of standardisation is 2009.13
0
500
1000
1500
2000
2500
3000
1980 1985 1990 1995 2000 2005d
ea
th
s/
ad
m
is
si
on
 p
er
 1
00
,0
00
Year
Men
0
500
1000
1500
2000
2500
3000
1980 1985 1990 1995 2000 2005d
ea
th
s/
ad
m
is
si
on
 p
er
 1
00
,0
00
Year
Women
 CVD admission CVD mortality
additional risk factors. Obesity and a parental history of MI before age 60 were considered 
additional risk factors. However, it was not known whether these additional risk factors 
improved risk prediction when added to the classical risk factor function.
The aim of this thesis was to improve cardiovascular risk prediction in the Netherlands. The 
following research questions were raised during the development of the first Guideline 
on Cardiovascular Risk Management (CVRM, 2006):14
1. Which SCORE risk function fits best for the Netherlands?
2. What are the consequences of a change from predicting CVD mortality 
to total CVD (fatal plus nonfatal) for identifying high-risk persons?
3. What is the added value for risk prediction of including additional risk 
factors (obesity and parental history of myocardial infarction) in the 
classical risk function with total CVD as endpoint? 
Main findings
The main findings, summarised in Table 7.1, are:
• The Netherlands was considered a high-risk CVD mortality country, but is 
now a low-risk country, for which the SCORE low-risk function fits best;
• The change from predicting CVD mortality to total CVD (fatal plus 
nonfatal) did not improve discrimination between future cases and 
non-cases; 
• Obesity (BMI ≥ 30 kg/m2) and parental history of myocardial infarction 
before age 70 were independent predictors of total CVD;
• Adding obesity and parental history to a classical risk factor function 
modestly improved correct risk classification; 
• The currently used cut-off points of 5% CVD mortality and 20% total CVD 
only identified individuals at very high risk;
• Cut-off points of 2% CVD mortality or 10% total CVD could be considered 
for identification of high-risk persons. 
Several findings contributed to the 2011 revision of the Guideline on CVRM.15 Since absolute 
risks of total CVD better reflect the high burden of CVD, the endpoint of risk prediction 
was changed from predicting CVD mortality to total CVD. Therefore the absolute fatal CVD 
risks – now calculated with the low-risk SCORE function – were multiplied by age-specific 
total-to-fatal CVD ratios. The new threshold for high-risk persons became 20% total CVD 
risk. The decision to include myocardial infarction, stroke and heart failure in the definition 
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of nonfatal CVD was taken after discussions in the 2011 Guideline working group. We found 
that body mass index and waist circumference were equally strong predictors of CVD. 
Therefore, the advice in the 2006 Guideline ‘to measure always both body mass index 
and waist circumference’ was changed to ‘measuring body mass index and possibly waist 
circumference’ in the 2011 Guideline. This simplification was also prompted by practical 
reasons. The age for a premature parental history of MI was changed from < 60 years to 
< 65 years in the 2011 Guideline. However, since improvements in risk prediction of adding 
obesity and parental history of MI into a classical risk factor model were modest, these 
risk factors were not incorporated into the risk function predicting total CVD. In the 2011 
Guideline, these risk factors are considered to be additional factors, to take into account 
when considering to prescribe drug treatment for those with an intermediate CVD risk.
An important finding, not included in the 2011 Guideline, was the fact that the cut-off 
points for 10-year risk of 5% CVD mortality and 20% for total 10-year CVD identified only 
individuals at very high risk. The results presented in this thesis suggest that thresholds 
for identification of high-risk persons could be lowered from 5 to 2% for CVD mortality 
and from 20 to 10% for total CVD. These lower thresholds will identify approximately 
10% of future total CVD events. Recently, the American Heart Association lowered the 
treatment threshold of total CVD to 10% for women, because statins were cost-effective 
at this threshold.16 Whether such a lowering of threshold is also cost-effective for Dutch 
men and women, needs to be investigated.
Strategies to further improve CVD risk prediction
Current risk prediction functions include mostly only classical risk factors. However, risk 
classification may improve by adding other risk factors17 such as: 
• easy to measure risk factors e.g. obesity, parental history of MI, heart 
rate,
• markers of inflammation e.g. C-Reactive Protein (CRP), Interleukin-6,
• markers of endothelial function e.g. intercellular and vascular cell 
adhesion molecules (ICAM, VCAM),
• markers of thrombosis e.g. fibrinogen,
• vascular markers of atherosclerosis e.g. carotid intima-media thickness 
(CIMT), coronary artery calcium score (CACS),
• CHD-related genetic variants e.g. on chromosome 10q11 or 9p21. 
We added obesity and parental history of premature myocardial infarction to a classical 
risk function. In men, adding obesity, improved the Net Reclassification Index (NRI) 
significantly by 3.8% and parental history of myocardial infarction not-significantly by 
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2.7% using risk categories of 10%. For women these percentages were not significant and 
amounted to 2.7% and 0.6%. Similar percentage of improvements were found in studies in 
which the effect was assessed of 45 potential predictors.17 The most common predictors 
included CRP and genetic variants such as on chromosome 9p21. In 38 studies, the NRI 
was calculated and ranged from -3.2% to 39% after adding biomarkers alone or combined. 
In studies with information on confidence intervals, the NRI was 2% (95% CI 0.5%–3.5%) 
in studies with an adequate baseline model versus 0.7% (0.2%–1.3%) in other studies. The 
NRI was 0.7% (0.1%–1.2%) in studies with justified risk thresholds versus 1.9% (0.5%–3.4%) in 
other studies. The highest NRIs were found for CRP.
Imaging techniques such as ultrasound measurements and computed tomography have 
been used to measure CIMT and CACS in order to quantify atherosclerosis. Eight studies 
investigated the added value of CIMT to classical risk factor functions and observed 
small, but sometimes significant improvements in area under the ROC curve.18 A recent 
study showed a 10% improvement in CHD risk prediction when CIMT and the presence of 
plaque were added.19 Adding CACS resulted in a NRI of 25%.20 Although these results are 
promising, additional data are required on the relationship between these measures and 
future CVD events before definitive conclusions can be drawn about the usefulness of 
adding these markers to risk functions.21
Implications of risk stratification for public health
An important finding of this thesis was the low number of high-risk persons in the 
participants in the Dutch MORGEN and PEILSTATION cohorts (aged 20–65 years). Less 
than 10% of the men and 1% of the women exceeded the 5% CVD mortality threshold for 
increased risk (Figures 2.1 and 5.3). These low numbers cannot fully be explained by the 
‘healthy cohort’ effect. Although in this high-risk group, about one in four individuals will 
develop a future CVD event, more than 84% of all male and 98% of all female future cases 
occurred in those at low or intermediate risk. Using the current thresholds, many future 
cases remain untreated, unless additional risk factors are present. Therefore to reduce 
the burden of CVD, also a total population strategy is needed.
The population strategy was for the first time described in a classic paper by Geoffrey Rose, 
published in the 1980s.22,23 Cooney et al. re-evaluated the population strategy proposed 
by Rose.24 A simulation study was carried out using SCORE data of persons aged 24–80 
years, assuming 10% reductions in prevalence of smoking and in serum cholesterol and 
blood pressure levels by preventive interventions. This would save 9,125 lives per million 
persons. They also showed that treating high-risk individuals (men aged ≥ 40 or women 
aged ≥ 50 years, and ≥ 5% CVD mortality risk) with a polypill – containing a statin, three 
half-dose antihypertensives and aspirin – with a 20–80% uptake, would save 1,861–7,452 
lives per million persons. This analysis suggests that the high-risk strategy is less effective. 
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Wald and Law proposed to treat the whole population aged 55 and older with a polypill.25 
They calculated that in theory, 84% of all CVD cases would be prevented. Recent studies 
showed that the effect of the polypill on CVD risk factors was moderately lower than 
predicted.26 Pitfalls in this medical approach to prevention are the potential costs of the 
polypill, adverse effects and medicalisation.27 Furthermore, the medical approach does 
not eliminate the causes of high risk factor levels. 
Safer and more sustainable ways of reducing risk factors in the population can be realised 
by lifestyle and dietary interventions.27 Examples of such approaches include smoking 
bans in public offices and restaurants, and salt and trans fats reductions in foods. With 
this type of lifestyle and environmental modifications large scale reductions in CVD and 
other chronic disease events can be achieved without side effects.28
Conclusion
People with a high risk should be correctly identified. Expanding  the endpoint of risk 
prediction from fatal to total CVD did not improve risk discrimination between future 
cases and non-cases, and adding additional risk factors to the classical risk factor 
function, modestly improved identification of high risk persons. Those with CVD risks 
comparable to that of CVD patients, should be adequately treated. This can be done 
through effective medication to counteract high levels of blood pressure and serum 
cholesterol, in combination with lifestyle measures. However, to reduce the large burden 
of CVD in the population, this is not enough, because most CVD cases occur in people 
with an intermediate or low risk. Therefore, alongside a high-risk strategy, a population 
approach is also needed. Fortunately, this can be done by diet and lifestyle interventions. 
Prospective cohort studies have shown that modifiable factors such as smoking, an 
unhealthy diet, overweight, and physical inactivity account for 80% of the occurrence 
of CVD.29 This means that a healthy diet and lifestyle are powerful tools to reduce the 
burden of CVD in the population.
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Cardiovascular diseases are the main cause of death in the Netherlands. In 2010, 28% of the 
men and 30% of the women died from this cause of death. It is estimated that every year, 
about 85,000 new coronary heart and 46,000 stroke events occur. Risk of cardiovascular 
diseases can be reduced by a healthy lifestyle and by pharmacological treatment of risk 
factors such as a high blood pressure and/or a high serum cholesterol. The first Dutch 
clinical guidelines on the identification and treatment of persons with high levels of these 
risk factors were developed in the 1980s, and are characterised by separate treatment of 
individual risk factors.
Over time interest in an integrated approach of treatment of risk factors for cardiovascular 
diseases increased. Around the year 2000, by implementation of the American Framingham 
risk charts in the Netherlands, multifactorial treatment of cardiovascular risk factors in 
clinical practice was introduced. With this tool, clinicians could calculate a patient’s risk 
of developing cardiovascular diseases in the next 10 years. This risk calculation is based 
on the classical risk factors age, sex, smoking status, systolic blood pressure and the ratio 
of total-to-HDL cholesterol.
In the Dutch multidisciplinary guideline on cardiovascular risk management (CVRM) in 
2006, guidelines on the identification and treatment of high-risk persons were updated 
according to the scientific state of the art of that time. The American risk charts were 
replaced by the European SCORE (Systematic Coronary Risk Evaluation) risk charts. This 
new risk function and chart predicted the risk of dying from cardiovascular diseases in the 
next 10 years. During the development of this guideline, several questions were raised, 
which will be treated in the research for this thesis. Some results of this research have 
been included in the guideline CRVM, which will be published at the end of 2011.
The aim of this thesis was to improve cardiovascular risk prediction in the Netherlands. 
The research questions investigated in this thesis are: 
1. Which SCORE risk function fits best for the Netherlands?
2. What are the consequences of a change from predicting fatal cardiovascular diseases 
to total (fatal or nonfatal) cardiovascular diseases for the identification of high-risk 
persons?
3. What is the added value for risk prediction of including the additional risk factors 
obesity and parental history of myocardial infarction in the classical risk function with 
total cardiovascular diseases as endpoint?
To deal with the first question, we examined data from two cohorts of the National 
Institute for Public Health and the Environment (RIVM). Risk factors of 36,000 persons 
were measured between 1987 and 1992 (Monitoring Project on Cardiovascular Disease 
Risk Factors; Peilstations project) and of 23,000 persons between 1993-1997 (Monitoring 
Project on Chronic Disease Risk Factors; MORGEN project). For the second question, 
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alongside the MORGEN project data, baseline measurements from the PROSPECT cohort of 
the University Medical Centre of Utrecht were also used. For the third question, MORGEN 
project data were used. These cohorts have been linked to the national population register 
(GBA), the Statistics Netherlands (CBS) register of cause of death and the National Hospital 
Discharge Register (LMR). By linking these data, it is now known which cohort members 
experienced a cardiovascular disease and who died from cardiovascular diseases.
The introduction to this thesis presents an historical overview of Dutch guideline 
development on treatment of hypertension and hypercholesterolemia. In particular, the 
change from an unifactorial to a multifactorial approach (cardiovascular risk management) 
and the role of risk charts in clinical practice, are described.
Chapter 2 describes how well 10-year cardiovascular disease mortality observed in the 
Dutch cohorts in the last two decades is predicted by three different SCORE risk functions: 
the risk function for low risk European countries (e.g. Mediterranean countries), the risk 
function for high risk European countries (e.g. Scandinavian countries and the Netherlands) 
and the nationally adapted Dutch SCORE risk function (published in the 2006 CVRM 
guideline). It turned out that the function for low-risk Mediterranean countries fitted 
the Dutch situation best. The SCORE risk function for high-risk European regions and the 
adapted Dutch SCORE risk function overestimated the number of cardiovascular disease 
deaths by a factor of 1.5-2. Use of these latter risk functions can lead to overtreatment 
with drugs to lower high blood pressure and high cholesterol levels. The reason for this 
overestimation is the fact that these risk functions were developed on data collected in 
the 1970s and early 1980s. Since then there has been a dramatic decline in cardiovascular 
disease mortality in the Netherlands, which has continued in recent years. 
To improve cardiovascular risk prediction to correctly classify high-risk persons for 
cardiovascular diseases, we investigated the impact of expanding the endpoint of risk 
prediction from 10-year risk of cardiovascular diseases mortality to 10-year risk of total 
(fatal + nonfatal) cardiovascular diseases (chapter 5), and of adding additional risk factors 
to the classical risk function (chapter 6). Two promising, easy to measure, risk factors are 
obesity and a parental history of myocardial infarction. Firstly, we conducted studies to 
examine the associations between measures of overweight and observed cardiovascular 
diseases (chapter 3), and between various definitions of parental history of myocardial 
infarctions and observed cardiovascular diseases (chapter 4). 
We studied the association between body mass index (BMI) and waist circumference, 
and 10-year incidence of fatal and nonfatal cardiovascular diseases in 20,000 men and 
women aged 20-65 years (chapter 3). About half of the men and women had an increased 
weight (BMI ≥25 kg/m2) and/or an increased waist circumference (≥94 cm in men and ≥80 
cm in women). During a 10-year follow-up period, 5.7% of the participants experienced a 
cardiovascular disease and 0.6% died from this cause. Nonfatal cardiovascular diseases 
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occurred 10 times more often than fatal cardiovascular diseases. Obese persons (BMI 
≥30 kg/m2) had a four-fold higher risk of dying from cardiovascular diseases and a two-
fold higher risk of developing a cardiovascular disease compared with normal-weight 
individuals (BMI 18.5-30 kg/m2). Similar associations were found for persons with a 
high waist circumference compared to those with a low waist circumference, meaning 
that both measures of overweight were equally strong predictors of fatal and nonfatal 
cardiovascular diseases. 
Of all 10,524 participants aged 40-65 years at baseline, 36% had one or two parents who had 
already experienced a myocardial infarction (chapter 4). Participants with a father alone, 
a mother alone or both parents with a history of myocardial infarction (irrespective the 
age of onset of the myocardial infarction) had a 30%, 50% and 60%, respectively, increased 
cardiovascular risk themselves compared to those with parents without a history of a 
myocardial infarction. The age of onset at which the myocardial infarction in the parent 
occurred, had an impact on the magnitude of the cardiovascular risk. Participants who 
had a father with a myocardial infarction between age 60 and 70 or below age 60 had an 
increased cardiovascular risk of 40% and 50% respectively. Those who had a mother with 
a myocardial infarction between age 60 and 70 or below age 60 had an increased risk of 
80% and 120%, respectively. Women, who had a mother with a myocardial infarction below 
age 60, had the largest cardiovascular risk (200%) compared to women with a mother 
without a myocardial infarction. 
The currently used SCORE risk charts in clinical practice, predict 10-year risk of dying from 
cardiovascular diseases. Over the last 40 years, mortality from these causes has gradually 
declined in the Netherlands, while the number of hospital admissions remained high. It is 
pertinent to ask, therefore, whether risk prediction could be improved by developing risk 
charts predicting risk of fatal or nonfatal cardiovascular diseases (chapter 5). 
Firstly, nonfatal cardiovascular diseases were defined by the occurrence of a myocardial 
infarction, stroke or heart failure only. During a period of 10 years, about four times as 
many participants experienced a cardiovascular disease event (nonfatal or fatal) than 
those who experienced a fatal event. Based on the Dutch data, risk functions were 
developed using Cox proportional hazard models for both endpoints of risk prediction. 
As measure to express how well these functions predict the patients who will and who 
will not experience an event (called risk discrimination), the Area Under the ROC curve 
was calculated. It turned out that both risk functions performed equally well. 
Changing from a risk function which predicts fatal to a risk function predicting total 
cardiovascular diseases will alter the risk threshold for prescribing drug treatment for 
high blood pressure and/or high serum cholesterol. This threshold for fatal cardiovascular 
diseases is 5% (European guidelines) and corresponded with a threshold of 20% for total 
cardiovascular disease. Of all persons with such a high risk, one in five actually will develop 
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cardiovascular diseases in a period of 10 years. While considering developing cardiovascular 
diseases in one in ten persons treated with drugs, a threshold of 2% cardiovascular 
mortality corresponded with a threshold of 10% total cardiovascular diseases. When 
medical treatment of 10 persons – leading to 1 case of cardiovascular disease – would be 
cost-effective, lowering treatment thresholds could be proposed.
The classical risk function includes the following risk factors: age, sex, smoking status, 
systolic blood pressure and the ratio of total-to-HDL cholesterol. We expanded this risk 
function by adding two easy to measure risk factors: the presence or absence of obesity 
and/or having a father or mother who experienced a myocardial infarction below age 
70 (chapter 6). Subsequently, the improvement in risk classification was measured 
by calculating the Net Reclassification Index. Patients who went on to develop a 
cardiovascular disease within10 years, should be ideally classified into the high-risk category 
to be eligible for drug treatment for high blood pressure and high serum cholesterol 
levels. Those who stay free of cardiovascular diseases, should be classified into a low-risk 
category. It was calculated that about 5% of the men were reclassified in the correct risk 
category by using the expanded risk function compared to the classical risk function. This 
moderate improvement was mainly due to adding obesity to the risk function, and, to a 
lesser extent, by adding having a parent with a myocardial infarction. Risk improvements 
in women were about 3%, but were not significant.
In chapter 7, the contribution of this PhD research to the revision of the 2006 Dutch 
guideline on cardiovascular risk management is described. In the 2011 guideline a 
change in risk tables predicting fatal cardiovascular diseases to those predicting total 
cardiovascular diseases was made, because medical doctors prefer to use risk tables with 
absolute risks expressing the total burden of cardiovascular diseases. These absolute 
risks were calculated by using the SCORE risk function for low-risk countries multiplied by 
age-dependent factors expressing the ratio of total-to-fatal cardiovascular diseases. The 
choice of this risk function and the multipliers are based on the research described in this 
thesis. Results from the association studies influenced the preference for using the body 
mass index in risk assessment and increased the parental age of onset of the myocardial 
infarction as additional risk factor, from below 60 to below 65 years. 
The moderate improvements in risk classification of high-risk persons by adding obesity 
and parental history of myocardial infarction to the classical risk function in our study 
were compared with risk improvements in other studies by adding risk factors and 
biomarkers of inflammation, endothelial function, thrombosis and atherosclerosis. In 
general, our findings are of the same magnitude as found in other biomarker studies. 
So far, the most promising results have been found in studies adding biomarkers of 
inflammation (C reactive-protein) and markers of atherosclerosis e.g. carotid intima-
media thickness.
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In our study, it was demonstrated that one in five high-risk persons actually developed 
a cardiovascular disease within a follow-up period of 10 years. However, in our cohorts, 
the total number of persons with such a high risk was less than 10%. This means that most 
cases of cardiovascular diseases occur among those at low or moderate risk. Therefore, to 
reduce the total burden of cardiovascular diseases a population-wide approach is proposed 
in addition to the high-risk approach as described in this thesis. Such a strategy includes 
nationwide measures to promote a healthy lifestyle.
The conclusion of this thesis is that current Dutch risk prediction of cardiovascular diseases 
and identification of the correct persons for drug treatment of high blood pressure and/
or high serum cholesterol can be improved by using the SCORE risk function for low-risk 
countries. Adding the risk factors obesity and parental history of myocardial infarction 
below age 70 to the classical risk function, will only lead to moderate risk reclassification 
improvements of high-risk persons.
By a change from predicting risk of fatal cardiovascular disease to risk of fatal or nonfatal 
cardiovascular disease, thresholds for drug treatment will increase from 5% to 20%. Of all 
persons with such a high risk, one in five will go on to develop a cardiovascular disease 
within 10 years. By lowering treatment thresholds to 2% for fatal cardiovascular disease and 
10% for fatal or nonfatal cardiovascular disease, one in 10 treated persons will develop a 
cardiovascular disease in the next 10 years. Cost-effectiveness studies have to demonstrate 
whether lowering treatment thresholds can be justified.
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(Summary in Dutch)
Hart- en vaatziekten zijn een belangrijke doodsoorzaak in Nederland. In 2010 stierf 
28% van de mannen en 30% van de vrouwen hieraan. Naar schatting komen er jaarlijks 
85.000 nieuwe gevallen van coronaire hartziekten en 46.000 van een beroerte bij. De 
kans op hart- en vaatziekten kan verlaagd worden door een gezonde leefwijze en door 
medicamenteuze behandeling van risicofactoren zoals een hoge bloeddruk en/of een 
hoog cholesterolgehalte in het bloed. De eerste Nederlandse medische richtlijnen voor 
de identificatie en behandeling van personen met hoge waarden van deze risicofactoren 
dateren uit de tachtiger jaren van de vorige eeuw en kenmerken zich door een gescheiden 
aanpak van de individuele risicofactoren.
De belangstelling voor een integrale aanpak van risicofactoren voor hart- en vaatziekten 
groeide in de loop der jaren. Met de komst van risicotabellen, gebaseerd op de Amerikaanse 
Framingham risicofunctie werd rond het jaar 2000 een multifactoriële aanpak van 
risicofactoren voor hart- en vaatziekten in de medische praktijk geïntroduceerd. Met dit 
hulpmiddel konden artsen de kans van een patiënt bepalen om in de komende 10 jaar 
een hart- of vaatziekte te ontwikkelen. Deze risicoschatting ging uit van de klassieke 
risicofactoren leeftijd, geslacht, het rookgedrag, de systolische bloeddruk en de 
verhouding totaal-cholesterol/HDL-cholesterol. 
In de multidisciplinaire richtlijn Cardiovasculair risicomanagement (CVRM), uitgebracht 
in 2006, werden de richtlijnen voor de identificatie en behandeling van hoogrisico 
personen opnieuw aangepast aan de wetenschappelijke stand van zaken van die tijd. De 
Amerikaanse tabellen werden vervangen door de Europese SCORE (Systematic COronary 
Risk Evaluation) risicotabellen. Deze nieuwe functie voorspelde de kans om binnen 10 jaar 
te overlijden aan een hart- of vaatziekte. Tijdens de richtlijnontwikkeling kwamen enkele 
onderzoeksvragen naar voren, die in dit proefschrift worden behandeld. De bevindingen 
hebben geleid tot aanpassingen in de richtlijn CVRM die in 2011 wordt uitgebracht. 
Doel van dit promotieonderzoek was om het voorspellen van de kans op hart- en vaatziekten 
in Nederland te verbeteren. De vraagstellingen onderzocht in dit promotieonderzoek zijn:
1. Welke SCORE risicofunctie past het beste bij Nederland?
2. Wat zijn de gevolgen voor het identificeren van hoogrisico personen van een overstap 
van risicofuncties die de kans op sterfte aan hart- en vaatziekten voorspellen naar 
risicofuncties die de kans op ziekte of sterfte aan hart- en vaatziekten voorspellen?
3. Kan de kans op ziekte en sterfte aan hart-en vaatziekten beter voorspeld worden 
door het toevoegen van extra risicofactoren aan de risicofunctie, namelijk ernstig 
overgewicht en het hebben van ouders die een hartinfarct hebben gehad?
Om antwoord te geven op de eerste vraagstelling zijn gegevens geanalyseerd van een 
tweetal monitoring-projecten van het Rijksinstituut voor Volksgezondheid en Milieu 
(RIVM), waarbij de risicofactoren van 36.000 personen werden gemeten in de periode 
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1987-1992 (Peilstationsproject Hart- en Vaatziekten) en van 23.000 personen tussen 1993 
en 1997 (MORGEN-project). Voor de tweede vraagstelling zijn naast de gegevens van 
het MORGEN-project, ook die van het PROSPECT-cohort van het Universitair Medisch 
Centrum Utrecht gebruikt. Voor de derde vraagstelling is gebruikgemaakt van het 
MORGEN-project. De cohorten zijn gekoppeld aan de Gemeentelijke Basis Administratie 
(GBA), de doodsoorzakenstatistiek van het Centraal Bureau voor de Statistiek (CBS) en 
aan de landelijke medische registratie van ziekenhuisopnamen (LMR). Daardoor is bekend 
wie er in de 10 jaar na meting van de risicofactoren een hart- of vaatziekte kreeg en wie 
daaraan is overleden. 
In de introductie van dit proefschrift wordt een historisch overzicht van de ontwikkeling 
van behandelrichtlijnen voor verhoogde bloeddruk en verhoogde cholesterolgehaltes in 
Nederland gepresenteerd (hoofdstuk 1). In het bijzonder wordt de overstap beschreven van 
een unifactoriële aanpak naar een multifactoriële aanpak (cardiovasculair risicomanagement) 
en de rol hierbij van de introductie van risicotabellen in de klinische praktijk.
In hoofdstuk 2 wordt aangegeven in welke mate de in Nederland waargenomen sterfte 
aan hart- en vaatziekten in de laatste twee decennia voorspeld kon worden door de drie 
– door de SCORE groep ontwikkelde –  risicofuncties: de functie voor laagrisico landen 
in Europa (bv. Mediterrane landen), die voor hoogrisico landen (bv. Scandinavische 
landen en Nederland) en de voor Nederland aangepaste risicofunctie (gepubliceerd in de 
richtlijn CVRM 2006). Het bleek dat de functie voor Mediterrane landen het best past bij 
de huidige Nederlandse situatie. De twee andere functies voorspelden 1,5 à 2 maal zoveel 
sterfgevallen aan hart- en vaatziekten dan daadwerkelijk werd waargenomen. Dit kan 
leiden tot overbehandeling met medicijnen ter verlaging van verhoogde bloeddruk- en 
cholesterolwaarden. De reden van de overschatting door twee van de SCORE risicofuncties 
is dat deze functies opgesteld zijn op basis van gegevens uit de zeventiger en begin 
tachtiger jaren, terwijl sindsdien de sterfte aan hart- en vaatziekten in Nederland sterk 
gedaald is en ook in recentere jaren gestaag blijft afnemen.
Om het voorspellen van de kans op hart- en vaatziekten te verbeteren en personen in 
een juiste risicocategorie in te delen, zijn twee zaken onderzocht. Enerzijds is onderzocht 
wat de invloed was van het veranderen van het eindpunt van de risicoschatting van de 
10-jaars kans op sterfte aan hart- en vaatziekten naar de 10-jaars kans op ziekte en sterfte 
aan hart- en vaatziekten (hoofdstuk 5). Anderzijds is onderzocht wat de invloed was van 
het toevoegen van extra risicofactoren aan de klassieke risicofunctie (hoofdstuk 6). Twee 
gemakkelijk te meten risicofactoren zijn obesitas en het hebben van ouders die reeds 
een hartinfarct hebben doorgemaakt. Allereerst onderzochten we het verband tussen 
verschillende maten van overgewicht (hoofdstuk 3) en tussen verschillende definities 
van het hebben van ouders met een hartinfarct (hoofdstuk 4) en de kans op hart- en 
vaatziekten.
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In hoofdstuk 3 worden de associaties van de body mass index (BMI) en middelomtrek 
met hart- en vaatziekten beschreven. Van de 20.000 mannen en vrouwen in de leeftijd 
van 20-65 jaar had ongeveer de helft een te hoog gewicht (BMI ≥25 kg/m2) en/of te grote 
middelomtrek (mannen ≥94 cm en vrouwen ≥80 cm). In een periode van 10 jaar kreeg 
5,7% van de deelnemers een hart- of vaatziekte en overleed 0,6% hieraan. Niet-fatale hart- 
en vaatzieken  kwamen dus 10 keer vaker voor dan fatale hart- en vaatziekten. Personen 
met obesitas (BMI ≥30 kg/m2) hadden een viermaal grotere kans om te sterven aan 
hart- en vaatziekten en een tweemaal grotere kans om een hart- of vaatziekte te krijgen 
dan personen met een gezond gewicht (BMI 18.5-25 kg/m2). Deze hogere risico’s golden 
ook voor personen met een hoge ten opzichte van een lage middelomtrek. Beide maten 
leverden een vergelijkbare schatting op van de kans op hart- en vaatziekten en -sterfte.
Van de 10.524 deelnemers in de leeftijdsklasse 40-65 jaar had bij de basismeting van 
risicofactoren 36% één of twee ouders die getroffen waren door een hartinfarct (hoofdstuk 
4). Het hebben van alleen een vader, alleen een moeder of beide ouders met een hartinfarct 
(ongeacht de leeftijd waarop) betekende respectievelijk een 30%, 50% of 60% hogere kans 
voor de deelnemer zelf om een hart- of vaatziekte te krijgen ten opzichte van deelnemers 
met ouders zonder hartinfarct. Als de vader een hartinfarct had gekregen tussen het 60een 
70e jaar dan had de deelnemer zelf een 40% hogere kans op hart- en vaatziekten. Kreeg de 
vader al onder de 60 jaar een hartinfarct, dan was die kans 50% hoger. Als de moeder een 
hartinfarct had gekregen tussen het 60e en 70e jaar dan had de deelnemer zelf een 80% 
hoger risico op hart- en vaatziekten. Kreeg de moeder een hartinfarct onder de 60 jaar, 
dan was die kans zelfs 120% hoger. Vrouwen die een moeder hadden met een hartinfarct 
onder het 60e jaar liepen het grootste risico op hart- en vaatziekten met een 200% hogere 
kans ten opzichte van vrouwen met een moeder zonder hartinfarct.
De huidige SCORE risicotabellen die door artsen gebruikt worden, voorspellen de 10-jaars 
kans op sterfte aan hart- en vaatziekten. Aangezien de sterfte aan hart- en vaatziekten in 
Nederland in de afgelopen 40 jaar sterk gedaald is, terwijl het aantal ziekenhuisopnamen 
voor hart- en vaatziekten onverminderd hoog blijft, is de vraag of het schatten van het 
risico op hart- en vaatziekten verbeterd kan worden door tabellen te ontwikkelen met 
als eindpunt van de risicoschatting de kans op ziekte of sterfte aan hart- en vaatziekten 
(hoofdstuk 5). Allereerst werd ziekte gedefinieerd als het krijgen van een hartinfarct, 
beroerte of hartfalen. In een periode van 10 jaar kregen viermaal zo veel personen een 
hart- of vaatziekte (fataal + niet-fataal) dan er aan hart- en vaatziekten overleden. Op 
basis van de Nederlandse gegevens werden risicofuncties opgesteld met de kans op 
sterfte aan hart- en vaatziekten en de kans op ziekte of sterfte aan hart- en vaatziekten 
als eindpunt. Als maat om uit te drukken hoe goed voorspeld kan worden wie later een 
hart- of vaatziekte krijgt en wie niet (risicodiscriminatie genaamd), werd de AUROC (Area 
Under the ROC-curve) berekend. De risicofunctie die de kans op ziekte of sterfte aan hart- 
en vaatziekten voorspelde bleek echter niet beter in staat onderscheid te maken tussen 
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personen die later al dan niet een hart- of vaatziekte kregen, dan de functie die alleen de 
kans op sterfte aan hart- en vaatziekten voorspelde.   
Bij een overstap van risicofuncties die de kans op sterfte voorspellen naar risicofuncties die 
de kans op ziekte of sterfte aan hart- en vaatziekten voorspellen, verandert ook de drempel 
van het risico waarboven medicamenteuze behandeling ter verlaging van verhoogde 
waarden van de bloeddruk en/of cholesterol door artsen voorgeschreven wordt. Die 
behandeldrempel voor de kans op sterfte aan hart- en vaatziekten ligt boven de 5% in 
Europese richtlijnen en komt overeen met een behandeldrempel voor de kans op ziekte 
of sterfte aan hart- en vaatziekten boven de 20%. Boven deze drempels ontwikkelden ca. 
20% van de personen met zo’n hoog risico in een periode van 10 jaar een hart- of vaatziekte. 
Als we uit zouden gaan van ca. 10% gevallen van hart- en vaatziekten in een te behandelen 
groep, komt de drempel voor de kans op sterfte aan hart- of vaatziekten van 2% overeen 
met een drempel voor de kans op ziekte plus sterfte van 10%. Indien het behandelen van 
deze 10% nieuwe gevallen van hart- en vaatziekten kosteneffectief zou zijn, kan worden 
voorgesteld om de behandeldrempels te verlagen.
De klassieke risicofunctie omvat de risicofactoren leeftijd, geslacht, roken, de systolische 
bloeddruk en de verhouding totaal-cholesterol/HDL cholesterol. Aan deze risicofunctie 
zijn het al dan niet hebben van obesitas en een familiaire belasting (vader of moeder met 
hartinfarct voor het 70e jaar) toegevoegd (hoofdstuk 6). Deze factoren zijn eenvoudig 
te meten of na te vragen door artsen. Vervolgens is met de Net Reclassification Index 
berekend of zo meer personen in een juiste risicocategorie ingedeeld worden. Personen 
die later daadwerkelijk een hart- of vaatziekte krijgen zouden in een hogere risicocategorie 
terecht moeten komen om in aanmerking te komen voor medicamenteuze behandeling. 
Personen die geen hart- en vaatziekte krijgen zouden juist in een lage risicocategorie 
moeten belanden. Het bleek dat ongeveer 5% van de mannen in een passender 
risicocategorie terechtkwam indien beide risicofactoren toegevoegd werden aan de 
klassieke risicofunctie. Deze lichte verbetering was vooral het gevolg van het toevoegen 
van obesitas, en kwam in mindere mate door het hebben van ouders met een hartinfarct. 
De verbetering in de indeling in de juiste risicocategorie bij vrouwen was 3%, maar was 
niet significant. 
In hoofdstuk 7 wordt aangegeven wat dit promotieonderzoek bijgedragen heeft aan de 
herziene richtlijn Cardiovasculair Risico Management, die eind 2011 uitgebracht wordt. 
In deze richtlijn wordt de overstap gemaakt van risicotabellen die de kans op sterfte 
aan hart- en vaatziekten voorspellen naar tabellen die de kans op ziekte of sterfte aan 
hart- en vaatziekten voorspellen, omdat artsen in de absolute risico’s ook de ziektelast 
van hart- en vaatziekten tot uiting willen laten komen. De absolute risico’s om binnen 
10 jaar te sterven aan hart- en vaatziekten – berekend met de SCORE-risicofunctie voor 
laagrisico landen in Europa – werden vermenigvuldigd met een factor die de verhouding 
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weergeeft tussen ziekte plus sterfte aan hart- en vaatziekten en alleen sterfte aan hart- en 
vaatziekten. Deze factor verschilde per leeftijdsgroep. De keuze voor de risicofunctie en 
de omrekeningsfactoren zijn gebaseerd op dit promotieonderzoek. De bevindingen uit de 
associatiestudies hadden invloed op de keuze van de voorkeursmaat voor overgewicht 
(van het meten van de BMI én middelomtrek naar de BMI en optioneel de middelomtrek) 
bij het bepalen van het risicoprofiel. Ook hadden de uitkomsten invloed op de bepalende 
leeftijd waarop bij de ouder een hartinfarct optrad (van verhoogd risico onder de 60 jaar 
naar onder de 65 jaar).  
De lichte verbetering in indeling van hoogrisico personen in de juiste risicocategorie door 
het toevoegen van obesitas en het hebben van een ouder met een hartinfarct voor het 
70e jaar aan de klassieke risicofunctie werd vergeleken met resultaten van andere studies. 
Het gaat dan vooral om het toevoegen van biomarkers van ontsteking, endotheelfunctie, 
trombose en atherosclerose. Onze bevindingen liggen over het algemeen in dezelfde 
orde van grootte als die in studies waarin naar het additionele effect van biomarkers is 
gekeken. Veelbelovend zijn ontwikkelingen op het terrein van biomarkers van ontsteking 
(C-reactive protein) en van de mate van atherosclerose gemeten in de halsslagaders. 
In dit onderzoek is aangetoond dat één op de vijf hoogrisico personen binnen een periode 
van 10 jaar daadwerkelijk een hart- of vaatziekte ontwikkelt. Echter, het totaal aantal 
personen met een dergelijk risico is minder dan 10%. Dit betekent dat de meeste hart- en 
vaatziekten optreden bij personen met lage en middelhoge risico’s. Derhalve is naast de 
hoog-risicobenadering, zoals beschreven in dit proefschrift, een populatiebenadering 
voorgesteld met landelijke maatregelen ter bevordering van een gezonde leefwijze om 
hart- en vaatziekten verder terug te dringen.
De conclusie van dit promotieonderzoek is dat het voorspellen van de kans op een hart- of 
vaatziekte en het identificeren van de juiste personen voor medicamenteuze behandeling 
van een hoge bloeddruk en/of hoog cholesterol in het bloed in Nederland verbeterd kan 
worden door gebruik van de SCORE risicofunctie voor laagrisico landen. Het toevoegen 
van de risicofactoren obesitas en het hebben van vader of moeder met hartinfarct voor 
het 70e jaar aan de klassieke risicofunctie leiden slechts tot geringe verbeteringen in de 
classificatie van hoogrisico personen. 
Bij een overstap van het voorspellen van de kans op sterfte naar de kans op ziekte of sterfte 
aan hart- of vaatziekten, verandert de behandeldrempel van 5% naar 20%, wat inhoudt 
dat er 5 personen behandeld worden om 1 toekomstige case te voorkomen. Dit lijkt een 
vrij ‘strenge’ drempelwaarde. Het is daarom zinvol om kosteneffectiviteitsstudies uit te 
voeren om na te gaan of de drempelwaarde verlaagd kan worden naar 2% voor sterfte 
c.q. 10% ziekte of sterfte aan hart- en vaatziekten.
116
Summary
Dankwoord 
(Acknowledgements)
Lieve Rob, jij was het die me aanspoorde om na te denken over mijn toekomst. Daar is dit 
promotieonderzoek uit voortgekomen. 
Beste Hans en Marina, ik ben jullie zeer erkentelijk dat ik de ruimte kreeg om te gaan 
promoveren na de strategische heroriëntatie van de Nederlandse Hartstichting in 2006. 
Dat het een epidemiologisch onderwerp op het terrein van de risicofactoren voor hart- 
en vaatziekten zou worden, wist ik meteen. Het zal jullie niet verbaasd hebben dat het 
onderwerp ook paste  bij mijn werk, dat ik met hart en ziel doe. 
Beste Daan, al in het eerste gesprek kwamen mijn ideeën samen met die van jou. 
Dankzij jouw heldere visie, werd het een innovatief en uitdagend onderzoek. Wat was je 
enthousiast en betrokken bij mijn onderzoek, en wat reageer je bewonderenswaardig snel 
op nieuwe resultaten en teksten. Het was een kunst om die teksten zo kort en krachtig 
mogelijk te laten zijn. Jouw gevleugelde woorden ‘schrijven is schrappen’ heb ik maar al 
te vaak moeten horen. 
Beste Monique en Marianne, wat een fijne co-promotoren! Jullie betrokkenheid en inzet 
waren groot en onze overleggen waren altijd plezierig. Ik voelde me gesteund en gehoord. 
Aan jullie inhoudelijke en strategische adviezen heb ik veel gehad. Beste Monique, op 
moeilijke momenten stond je altijd klaar. En de gesprekken op de vrijdag over de dagelijkse 
voortgang en problemen waar ik tegenaan liep, heb ik zeer gewaardeerd. Beste Marianne, 
hoewel ik geen gebruik gemaakt heb van de data van de alpha-omega trial, heb ik je 
inbreng als zeer constructief ervaren. Als we er in discussies niet direct uitkwamen, was 
jij het vaak die met een creatieve oplossing kwam. Ik wens jullie beiden veel succes met 
de voortzetting van je carrière.
Beste Jolanda, mede-auteur van alle artikelen. Hartelijk dank voor je kritische opmerkingen 
bij de conceptversies van de artikelen. Ik kon altijd bij je terecht om methodologische 
aspecten van het onderzoek te bespreken. Dank daar voor.
Beste Hendriek, je gaf mij statistische adviezen of dacht mee over moeilijke SAS-syntaxen. 
Jouw intensievere bijdrage aan de laatste twee artikelen heeft er toe geleid dat je daarvan 
mede-auteur bent geworden. Dank voor je inbreng.
Beste Rick en Yvonne, dank voor het gebruik van de PROSPECT data van het UMCU 
en jullie constructieve commentaren op het 5e artikel dat in de loop der tijd meerdere 
transformaties heeft ondergaan. 
De leden van de leescommissie, de hoogleraren Frans Kok, Ian Graham, Arno Hoes en 
Ron Peters, dank ik voor het beoordelen van de kwaliteit van het manuscript en het 
opponeren. 
Beste Frans, in 1984 verliet je de Hartstichting en volgde ik je daar op. Inmiddels ben je 
hoofd van de Vakgroep Humane Voeding in Wageningen. Onze wegen kruisen elkaar 
opnieuw en ik stel het bijzonder op prijs dat je wilt opponeren. Dear Ian, I am proud 
118
Dankwoord       
of having such a famous cardiologist, the founding father of the SCORE risk charts, as 
an opponent. Beste Arno en Ron, bij de ontwikkeling van de richtlijn Cardiovasculair 
Risicomanagement was ik onder de indruk van jullie deskundige inbreng. Beste Ron, 
eerder hebben we prettig samengewerkt in het kader van de Werkgroep Cijfers. Nu wil 
ik je hartelijk danken voor je bereidheid om als opponent op te treden. 
Beste Hans Stam, ik voel me zeer vereerd dat je vanuit de zaal gaat opponeren. 
Hierbij dank ik de leden van de Werkgroep Cardiovasculair Risicomanagement voor de 
discussies over de analyses ten behoeve van de nieuwe risicotabel in de herziene Richtlijn 
Cardiovasculair Risicomanagement. Beste Karen Konings, lid van de Werkgroep en 
redacteur van de Richtlijn, wat fijn dat jij op het minisymposium spreekt.
Graag dank ik Monique Verschuren, Jet Smit en Jantine Schuitvoor de gelegenheid die jullie 
mij boden om het onderzoek uit te voeren bij het Rijksinstituut voor de Volksgezondheid 
en Milieu (RIVM) te Bilthoven. Ik heb dankbaar gebruik gemaakt van de RIVM data. Anneke 
Blokstra maakte mij wegwijs in de datasets en was altijd bereid me te helpen. Veel dank 
daarvoor.
Dat ik mij zeer welkom heb gevoeld bij het RIVM is ook te danken aan mijn gezellige 
kamergenoten. In het oude gebouw Anneke, Lucie en Petra, en voortgezet in het nieuwe 
gebouw met Petra. Ik zal jullie missen. En ook andere PZO collega’s onder wie Alet, 
Annemarie, Annemieke, Astrid, Boukje, Carolien, Ellen, Evert, Karin, Marianne, Marga, 
Marieke, Peter, Sandra, Susan, Wanda, Wien, Yvon hebben er toe bijgedragen dat ik me 
thuis voelde bij het RIVM. Annemieke, fijn dat je me als paranimf wilt bijstaan.
Beste Marieke, Linda en Janette, collega-promovendi. Onze promotietrajecten vonden in 
dezelfde periode plaats, we hadden dezelfde (co) promoteren, en waren allen verbonden 
aan zowel RIVM als WUR. We konden derhalve onze ervaringen delen, ook die met de 
opbouw van de datasets. Leuk om met jonge, enthousiaste mensen op te trekken. Ik heb 
ook plezierige herinneringen aan buitenlands congresbezoek. Marieke, jij moet nog verder. 
Ik wens je volgende jaar veel succes bij de afronding van jouw promotie.
De jaarlijkse overleggen op de Harstichting met Hans en Marina waren altijd plezierig 
en vol  enthousiasme. Presentatie van nieuwe onderzoeksresultaten leverde altijd weer 
ideeën voor aanvullend onderzoek op. Karin, dank dat je achter mijn onderzoek stond, 
alhoewel ik niet altijd bij teamzaken aanwezig kon zijn. Het was een drukke periode. 
Dankzij de inzet van  Ank en Marieke bij beleidsonderbouwend onderzoek en van Ilonca, 
die het secretarisschap van de Werkgroep Cijfers van mij overnam, bleef alles in goede 
banen lopen. Ik hoop nog veel met jullie samen te werken in de toekomst. 
Beste Ank en Hubert, ik vond altijd bij jullie een luisterend oor en kon lief en leed delen. 
Ank wat fijn dat je mij nu ook als paranimf zal steunen.
Vele collega’s leefden mee, in het bijzonder de collega’s van het team Wetenschap, Karin, 
Ank, Angela, Angelique, Annet, Annette, Carla, Els, Hubert, Ilonca, Marieke, Marty, Nanna, 
119
D
ankw
oord
Nelleke, Sylvia. En ook de collega’s van het programma Passie voor Preventie, in het 
bijzonder Désirée, Anne-Margreet, Hester, Marianne, Marijke.
Mijn onderzoek is uitgevoerd onder de auspiciën van onderzoeksschool VLAG en 
Wageningen Universiteit. Alhoewel ik weinig aanwezig ben geweest op de vakgroep 
Humane Voeding, vond ik het leuk om weer eens een kijkje in de keuken van mijn vroegere 
studieplek te nemen. Graag wil ik Lous Duym en collega’s danken voor het overbrengen van 
de commentaren van Daan en voor steun bij het regelwerk dat aan zo’n promotietraject 
vastzit.
Graag dank ik mijn familie, vrienden, kennissen en collega’s voor het meeleven met mijn 
onderzoek en de niet aflatende belangstelling voor mijn vorderingen. Vanaf heden zal ik 
mijn aandacht meer richten op de zaken waar jullie mee bezig zijn. 
Lieve papa en mama, jullie hebben me altijd gestimuleerd om een goede opleiding te 
volgen. Wat waren jullie trots toen ik aan Wageningen Universiteit afstudeerde. En nu 
weer een stap verder. Hoewel mama er niet meer is, de kaft van dit proefschrift is een 
eerbetoon aan haar.
Lieve Rob, wat hebben we het getroffen met elkaar. Tijdens de lange wandelingen 
met onze hond Yordi over de Edense hei bespraken we de vele onderwerpen rondom 
een promotie, van strategische keuzes tot het maatschappelijk belang van promotie 
onderzoek. Je bent zowel in je werk als privé een coach. Zonder jouw steun en massages, 
had ik het veel moeilijker gehad.
Lieve Jasmijn, tijdens het onderzoek groeide je op van basis- naar middelbare scholier. 
Wat doe je leuke dingen in je leven en wat ben je creatief! Jouw eerlijke, directe reacties 
schudden mij af en toe wakker uit het onderzoek en maakten dat ik ook aandacht aan 
mijn gezin besteedde. Helaas kon ik niet altijd mee shoppen, maar dat gaan we inhalen. 
Jij mag kiezen, maar wat denk je van shoppen in New York?
Ik ga nu heerlijk genieten van mijn vrije tijd en pak mijn activiteiten als natuurgids bij het 
IVN, vereniging voor natuur- en milieueducatie weer op. Maar het bloed kruipt, waar…
Nu het onderzoek afgerond is, gaat een lang gekoesterde wens in vervulling. Hartelijk 
dank aan een ieder die hieraan een bijdrage heeft geleverd en in het bijzonder aan Rob 
die mij op dit spoor bracht.
120
Dankwoord
About the author
CURRICULUM VITAE
Ineke van Dis graduated in 1975 from secondary school 
(gymnasium-β) at the Scholengemeenschap professor 
Casimir in Vlaardingen. 
Subsequently, she studied Human Nutrition at Wageningen 
University with specialisation natural sciences. In 1982 and 
1983 she was employed on short-term contracts at the 
Universities of Wageningen, Nijmegen and Maastricht. In 
the Department of Epidemiology of Maastricht University, 
she wrote a textbook with slides on the scientific state of 
the art on lifestyle and risk factors of cardiovascular diseases. 
Since 1983, she is working at the Netherlands Heart Foundation (NHF) as nutritionist, 
epidemiologist and policymaker. From 1983-1996 she was head of the NHF’s group of 
10 freelance dieticians and was responsible for health projects in company restaurants, 
health education meetings, supermarket tours on nutrition labelling and healthy 
cooking demonstrations. Furthermore, she is in charge of cardiovascular statistics and 
coordinated the publication of 16 books on cardiovascular statistics. She is also responsible 
for translating the scientific state of the art on nutrition, lifestyle and risk factors of 
cardiovascular diseases, into prevention policies and projects, and is spokeswoman on 
prevention topics. In 2001 and 2005 she was deputy head of the NHF’s Department of 
Prevention and Health Education and from 2002-2006 president of the NHF’s union. In 
2005, she participated in the NHF management team and was involved in a strategic re-
orientation of NHF policy.
In 1991 she became honorary member of the Dutch Association of Dieticians. In 1993 
she was registered as epidemiologist A and in 2006 as nutritional scientist A. She has 
participated in CBO working groups on Dutch guidelines on cholesterol (1987, 1999), 
cardiovascular risk management (2006, 2011) and obesity (2008), in the Health Council 
committee on cholesterol (1990) and in the European Heart Network’s nutrition working 
group. 
Since 2007, alongside her job as senior policymaker at the Research Department of the 
NHF, she conducted a PhD project on cardiovascular risk prediction in the Netherlands 
at the National Institute for Public Health and the Environment (RIVM) in Bilthoven, in 
collaboration with Wageningen University.
122
Curriculum vitae
PUBLICATIONS
Van Dis I, Kromhout D, Geleijnse JM, Boer JMA, Verschuren WMM. Paternal and maternal history 
of myocardial infarction and 10-year cardiovascular diseases incidence in a Dutch cohort of middle-
aged men and women. Accepted by PLoS ONE.
Van Dis I, Kromhout D, Geleijnse JM, Boer JMA, Verschuren WMM. Evaluation of cardiovascular 
risk predicted by different SCORE equations: the Netherlands as an example. Eur J Cardiovasc Prev 
Rehabil 2010; 17:244-249.
Vaartjes I, van Dis I, Grobbee DE, Bots ML. The dynamics of mortality in follow-up time after an acute 
myocardial infarction, lower extremity arterial disease and ischemic stroke. BMC Cardiovascular 
Disorders 2010; 10:57-65.
Nielen MMJ, Assendelft WJ, Drenthen AJM, van den Hombergh P, van Dis I, Schellevis FG. Primary 
prevention of cardio-metabolic diseases in general practice: a Dutch survey of attitudes and working 
methods of general practitioners. Eur J Gen Pract 2010; 16:139-142.
Blokstra A, van Dis I, Verschuren WMM. Efficacy of multifactorial lifestyle interventions in patients 
with established cardiovascular diseases and high risk groups. Eur J Cardiovasc Nursing 2010; 2 
december (epub ahead of print).
Scarborough P, Rayner M, van Dis I, Norum K. Meta-analysis of effect of saturated fat intake on 
cardiovascular disease: overadjustment obscures true associations. Am J Clin Nutr 2010; 92:458-459. 
(letter to the editor)
Van Dis I, Kromhout D, Geleijnse JM, Boer JMA, Verschuren WMM. Body mass index and waist 
circumference predict both 10-year nonfatal and fatal cardiovascular disease risk: study conducted 
in 20,000 Dutch men and women aged 20-65 years. Eur J Cardiovasc Prev Rehabil 2009; 16:729-734. 
Fransen GAJ, Hiddink GJ, Koelen MA, van Dis SJ, Drenthen AJM, van Binsbergen JJ, et al.  The 
development of a minimal intervention strategy to address overweight and obesity in adult primary 
care patients in the Netherlands. Fam Practice 2008; 25: Suppl. 1; I112-I115.
SUBMITTED PUBLICATIONS
Van Dis I, Geleijnse JM, Boer JMA, Kromhout D, Boshuizen H, Grobbee DE, van der Schouw YT, 
Verschuren WMM. Effect of including nonfatal events in cardiovascular risk prediction, illustrated 
with data from the Netherlands. (submitted)
Van Dis I, Geleijnse JM, Kromhout D, Boer JMA, Boshuizen H, Verschuren WMM. Do obesity and parental 
history of myocardial infarction improve cardiovascular risk prediction? (submitted) 
Van Dis I, Geleijnse JM, Verschuren WMM, Kromhout D. Cardiovascular risk management of hypertension 
and hypercholesterolemia in the Netherlands: from unifactorial to multifactorial approach. (submitted)
ABSTRACTS AND PRESENTATIONS AT EUROPEAN CONFERENCES
Van Dis I, Geleijnse JM, Kromhout D, Boer JMA, Verschuren WMM. Improving cardiovascular risk 
prediction by adding parental history of myocardial infarction. European Society of Cardiology 
Congress, Paris, 2011 (Presentation).
Van Dis I, Kromhout D, Geleijnse JM, Boer JMA, Verschuren WMM. Various definitions of parental 
history of myocardial infarction and cardiovascular risk in the Dutch MORGEN-cohort. EuroPRevent, 
Geneva, 2011 (Moderated poster presentation).
123
Publications
Van Dis I, Kromhout D, Geleijnse JM, Boer JMA, Verschuren WMM. The burden of non-fatal 
cardiovascular diseases and consequences for cardiovascular risk management. Eur Heart J 2010; 31 
(abstract suppl.): 597 / European Society of Cardiology Congress, Stockholm, 2010 (Presentation).
Van Dis I, Kromhout D, Geleijnse JM, Boer JMA, Verschuren WMM. The ratio of total to fatal 
cardiovascular disease incidence rates and implications for risk charts. EuroPRevent, Prague, 2010 
(Poster).
Nielen M, Assendelft P, Drenthen T, van den Hombergh P, van Dis I, Schellevis F. Prevention of 
cardiovascular diseases, diabetes and chronic kidney diseases in general practice. Swiss Medical 
Weekly 2009; 139: Suppl. 175, 20S (Poster).
Van Dis SJ, Kromhout D, Geleijnse JM, Verschuren WMM. SCORE for high risk areas overestimates 
the number of Dutch patients eligible for drug treatment. Eur Heart J 2008; 29:Suppl: 267 / European 
Society of Cardiology, München, 2008 (Presentation).
Van Dis SJ, Kromhout D, Geleijnse JM, Verschuren WMM. Cardiovascular mortality in the Netherlands 
is better predicted by the low-risk SCORE equation than by the high-risk SCORE equation. 
EuroPRevent, Paris, 2008 (Moderated poster presentation).
Vaartjes I, de Bruin A, van Dis SJ, Reitsma JB, Bots ML. Survival after first hospitalisation for acute 
myocardial infarction, ischemic stroke or intermittent claudication: mortality risk increases in time 
especially for male intermittent claudication patients. Circulation 2008 (Abstract).
Vaartjes I, de Bruin A, van Dis I, Reitsma JB, Bots ML. Long-term prognosis for men with claudicatio 
intermittens is much poorer than for men with AMI or stroke. American Heart Association. 48th 
Cardiovascular disease epidemiology and prevention annual conference 2008, Abstract P357 (Poster).
Vaartjes I, de Bruin A, van Dis I, Reitsma JB, Bots ML. Short- and long-term prognosis after 
cerebrovascular disease and acute myocardial infarction in the Netherlands. Circulation 2007; 115;69. 
Abstract P178 (Poster).
PUBLICATIONS IN DUTCH JOURNALS
Jonkers R, Gelissen RBM, Kremers SPJ, van Oosterhout MJW, van Dis I. Gezondheidstests ter 
vroegtijdige opsporing van cardiometabool en renaal risico: een verkenning van de kennis, houding 
en gedrag onder doelgroepen. Hart Bulletin 2011; 42;104-108
Vaartjes I, van Dis I, Bots ML. Hart- en vaatziekten bij kinderen tot en met 14 jaar. Hart Bulletin 2011; 
42:73-76.
Vaartjes I, van Dis I, Visseren FLJ, Bots ML. Sterfte aan hart- en vaatziekten in Nederland. Hart 
Bulletin 2011; 42:44-50.
Vaartjes I, van Dis I, Visseren FLJ, Bots ML. Incidentie en prevalentie van hart- en vaatziekten in 
Nederland. Hart Bulletin 2011; 42:18-24.
Vaartjes I, van Dis I, Bots ML. Ziekenhuisopnamen vanwege een beroerte. Hart Bulletin 2010; 41:150-
158.
Vaartjes I, van Dis I, Bots ML. Sterfte aan een beroerte. Hart Bulletin 2010; 41:129-132.
Vaartjes I, van Dis I, Visseren FLJ, Bots ML. Verschillen in sterfte aan hart- en vaatziekten tussen 
provincies in Nederland. Hart Bulletin 2010; 41:80-83.
Vaartjes I, van Dis I, Visseren FLJ, Bots ML. Ziekenhuisopnamen vanwege hart- en vaatziekten in 
Nederland. Hart Bulletin 2010; 41:52-55.
124
Publications
Vaartjes I, van Dis I, Visseren FLJ, Bots ML. Sterfte aan hart- en vaatziekten in Nederland. Hart 
Bulletin 2010; 41:19-23.
Vaartjes I, van Dis I, Bots ML, Visseren FLJ. Ingrepen bij patiënten met hartziekten in Nederland. 
Hart Bulletin 2009; 40:150-152.
Vaartjes I, van Dis I, Visseren FLJ, Bots ML. Hartinfarct. Hart Bulletin 2009; 40:129-130.
Vaartjes I, van Dis SJ, Peters RJG, Visseren FLJ, Bots ML. Verschillen tussen mannen en vrouwen in 
hart- en vaatziekten in Nederland. Hart Bulletin 2009; 40:19-25.
Blokstra A, van Dis SJ, Verschuren WMM. Verlaging van cardiovasculair risico door leefstijlinterventies 
bij patiënten met hart- en vaatziekten of hoog risico. Deel 2. Lichamelijke inactiviteit, roken, diabetes 
mellitus en multifactoriële interventies. Hart Bulletin 2008; 39:101-107.
Blokstra A, van Dis SJ, Verschuren WMM. Verlaging van cardiovasculair risico door leefstijlinterventies 
bij patiënten met hart- en vaatziekten of hoog risico. Deel 1. Cholesterol en voeding, overgewicht 
en bloeddruk. Hart Bulletin 2008; 39:74-78.
Kaasjager HAH, van Dis SJ. Cardiovasculaire risicofactoren bij patiënten met hart- en vaatziekten. 
Hart Bulletin 2008; 39:46-51.
Vaartjes I, van Dis SJ, Peters RJG, Bots ML. Ingrepen bij hartritmestoornissen, hartoperaties en 
percutane coronaire interventies. Hart Bulletin 2008; 39:21-23.
M. Deutekom, Aziz Y, van Dis I, Stronks K, Bossuyt PMM. De nationale cholesteroltest: vooral 
gezonde deelnemers. Ned Tijdschr Geneeskd 2008; 152:242-249.
Van Dis SJ, van Leest LATM, Verschuren WMM. Jongeren en hart- en vaatziekten. Hart Bulletin 
2007; 38:140-143.
Vaartjes I, van Dis SJ, Peters RJG, Bots ML. Hartinfarct. Hart Bulletin 2007; 38:112-114.
Vaartjes I, van Dis SJ, Peters RJG, Bots ML. Ziekenhuisopnamen voor hart- en vaatziekten. Hart 
Bulletin 2007; 38:85-86.
Vaartjes I, van Dis SJ, Peters RJG, Bots ML. Sterfte aan hart- en vaatziekten en kanker anno 2005. 
Hart Bulletin 2007; 38:20-31.
Van Leest LATM, Verschuren WMM, van Dis SJ. Leefstijl- en risicofactoren voor hart- en vaatziekten 
in de Nederlandse bevolking. Deel II. Overgewicht, verhoogd cholesterol, diabetes. Hart Bulletin 
2006; 37:165-168.
Van Leest LATM, Verschuren WMM, van Dis SJ. Leefstijl- en risicofactoren voor hart- en vaatziekten 
in de Nederlandse bevolking. Deel I. Roken, ongezonde voeding, lichamelijke (in)activiteit, 
alcoholgebruik en verhoogde bloeddruk. Hart Bulletin 2006; 37:139-142.
PUBLICATIONS ABOUT CARDIOVASCULAR DISEASES BY THE 
NETHERLANDS HEART FOUNDATION
Vaartjes I, van Dis I, Visseren FLJ, Bots ML. Hart- en vaatziekten in Nederland. In: Vaartjes I, van 
Dis I, Visseren FLJ, Bots ML (Red). Hart- en vaatziekten in Nederland 2010, cijfers over leefstijl- en 
risicofactoren, ziekte en sterfte. Den Haag: Nederlandse Hartstichting, 2010.
125
Publications
Vaartjes I, van Dis I, Visseren FLJ, Bots ML. Incidentie en prevalentie van hart- en vaatziekten in 
Nederland. In: Vaartjes I, van Dis I, Visseren FLJ, Bots ML (Red). Hart- en vaatziekten in Nederland 
2010, cijfers over leefstijl- en risicofactoren, ziekte en sterfte. Den Haag: Nederlandse Hartstichting, 
2010.
Vaartjes I, van Dis I, O‘Flaherty M, Capewell S, Bots ML. Trends in sterfte aan coronaire hartziekten 
in Nederland in de periode van 1972 tot 2007. In: Vaartjes I, van Dis I, Visseren FLJ, Bots ML (Red). 
Hart- en vaatziekten in Nederland 2010, cijfers over leefstijl- en risicofactoren, ziekte en sterfte. Den 
Haag: Nederlandse Hartstichting, 2010.
Vaartjes I, van Dis I, Visseren FLJ, Bots ML. Hart- en vaatziekten in Nederland. In: Vaartjes I, van 
Dis I, Visseren FLJ, Bots ML (Red). Hart- en vaatziekten in Nederland 2009, cijfers over leefstijl- en 
risicofactoren, ziekte en sterfte. Den Haag: Nederlandse Hartstichting, 2009.
Vaartjes I, van Dis I, Visseren FLJ, Bots ML. Ingrepen bij patiënten met hartziekten in Nederland. In: 
Vaartjes I, van Dis I, Visseren FLJ, Bots ML (Red). Hart- en vaatziekten in Nederland 2009, cijfers over 
leefstijl- en risicofactoren, ziekte en sterfte. Den Haag: Nederlandse Hartstichting, 2009.
Vaartjes I, van Dis I, Visseren FLJ, Bots ML. Verschillen in sterfte aan hart- en vaatziekten tussen 
provincies in Nederland. In: Vaartjes I, van Dis I, Visseren FLJ, Bots ML (Red). Hart- en vaatziekten 
in Nederland 2009, cijfers over leefstijl- en risicofactoren, ziekte en sterfte. Den Haag: Nederlandse 
Hartstichting, 2009.
Vaartjes I, Peters RJG, van Dis SJ, Bots ML. Hart- en vaatziekten in Nederland naar geslacht. In: 
Vaartjes I, Peters RJG, van Dis SJ, Bots ML (Red). Hart- en vaatziekten in Nederland 2008, cijfers 
over ziekte en sterfte. Den Haag: Nederlandse Hartstichting, 2008.
Blokstra A, van Dis SJ, Verschuren WMM. Effectiviteit van leefstijlinterventies bij patiënten met 
hart- en vaatziekten of hoog risico. Review RIVM/NHS, 2008.
Kok L, van Dis SJ, Verschuren WMM. Effectiviteit van leefstijlinterventies ter behandeling van 
hypertensie bij patiënten met hart- en vaatziekten of hoog risicopersonen. Review RIVM/NHS, 2008.
Kok L, van Dis SJ, Verschuren WMM. Effectiviteit van leefstijlinterventies ter behandeling van 
hypercholesterolemie bij patiënten met hart- en vaatziekten of hoog risicopersonen. Review RIVM/
NHS, 2008.
Blokstra A, van Dis SJ, Verschuren WMM. Effectiviteit van leefstijlinterventies ter behandeling van 
diabetes mellitus bij patiënten met hart- en vaatziekten of hoog risicopersonen. Review RIVM/
NHS, 2008.
Blokstra A, van Dis SJ, Verschuren WMM. Effectiviteit van beweeginterventies bij patiënten met 
hart- en vaatziekten of hoog risicopersonen. Review RIVM/NHS, 2008.
Bogers RP, van Dis SJ, Verschuren WMM. Effectiviteit van leefstijlinterventies ter behandeling van 
overgewicht bij patiënten met hart- en vaatziekten of hoog risicopersonen. Review RIVM/NHS, 2008.
van Gelder BM, van Dis SJ, Verschuren WMM. Effectiviteit van stoppen-met-roken interventies 
ter behandeling van overgewicht bij patiënten met hart- en vaatziekten of hoog risicopersonen. 
Review RIVM/NHS, 2008.
Blokstra A, van Dis SJ, Verschuren WMM. Effectiviteit van multifactoriële leefstijlinterventies bij 
patiënten met hart- en vaatziekten of hoog risicopersonen. Review RIVM/NHS, 2008.
Vaartjes I, Peters RJG, van Dis SJ, Bots ML. Hart- en vaatziekten in Nederland. In: Vaartjes I, Peters 
RJG, van Dis SJ, Bots ML (Red). Hart- en vaatziekten in Nederland 2007, cijfers over ziekte en sterfte. 
Den Haag, Nederlandse Hartstichting, 2007.
126
Publications
OVERVIEW OF COMPLETED TRAINING ACTIVITIES
Courses
• Linear regression, logistic regression, Cox regression and survival analysis. RIVM, 
Bilthoven, 2007
• Regression analysis by S. Lemeshow. Erasmus Summer Programme, Rotterdam, 2007 
• Survival analysis by D. Kleinbaum and M. Klein. Erasmus Summer Programme, 
Rotterdam, 2006 
Meetings
• European Society of Cardiology Congress. Vienna (2007), München (2008), Stockholm 
(2010), Paris (2011)
• EuroPRevent Congress. Paris (2008),  Prague (2010), Geneva (2011)
• 9th Euro Fed Lipids congress, Rotterdam, 2011
• 49th Cardiovascular disease epidemiology and prevention annual conference, and 
Nutrition, physical activity and metabolism conference. American Heart Association. 
Florida, USA, 2009
• Prediction in cardiovascular disease. Clinical and methodological perspectives. UMCU, 
Utrecht, 2009
• World Congress of Cardiology, Barcelona, 2006
• Annual meetings of NWO-nutrition, WEON and  EPIC-NL
• Meetings, seminars and conferences of learned societies (14) and universities (5)
General courses
• Team training by Focus. Leidschendam, 2010
• Media training by Burson-Marsteller. The Hague, 2006
• Communication, interaction and management by Van Harte & Lingsma. Leiden, 2002
Optionals
• CBO/NHG Working groups on Cardiovascular risk management (2006 and 2011), and 
Obesity (2008)
• Nutrition working group, European Heart Network, Brussels
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